UCSF UC San Francisco Previously Published Works

Title

Concerted epithelial and stromal changes during progression of Barrett's Esophagus to invasive adenocarcinoma exposed by multi-scale, multi-omics analysis

Permalink

https://escholarship.org/uc/item/52f920bd

Authors

Strasser, Michael K Gibbs, David L Gascard, Philippe <u>et al.</u>

Publication Date

2023-06-11

DOI

10.1101/2023.06.08.544265

Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at https://creativecommons.org/licenses/by/4.0/

Concerted epithelial and stromal changes during progression of Barrett's Esophagus to invasive adenocarcinoma exposed by multi-scale, multi-omics analysis

4

5 Michael K. Strasser^{1#}, David L. Gibbs^{1#}, Philippe Gascard², Joanna Bons³, John W. Hickey⁴, Christian M.

6 Schürch^{4,5}, Yuqi Tan⁴, Sarah Black⁴, Pauline Chu^{4,6}, Alican Ozkan⁷, Nathan Basisty³, Veena Sangwan⁸, Jacob

7 Rose³, Samah Shah³, Sophie Camilleri-Broet⁹, Pierre-Oliver Fiset⁸, Nicolas Bertos⁸, Julie Berube⁸, Haig

8 Djambazian¹⁰, Rui Li¹⁰, Spyridon Oikonomopoulos¹⁰, Daffolyn Rachael Fels-Elliott¹¹, Sarah Vernovsky⁷, Elee

9 Shimshoni⁷, Deborah Collyar¹², Ann Russell¹³, Ioannis Ragoussis¹⁰, Matthew Stachler², James R.

10 Goldenring¹⁴, Stuart McDonald¹⁵, Donald E. Ingber^{7#}, Birgit Schilling^{3#}, Garry P. Nolan^{4,6#}, Thea D. Tlsty^{2#},


11 Sui Huang^{1#*}, Lorenzo E. Ferri^{8#}

- 12 1. Institute for Systems Biology, Seattle, WA, USA
- 13 2. Department of Pathology, University of California, San Francisco, CA, USA.
- 14 3. The Buck Institute for Research on Aging, Novato, CA, USA
- 15 4. Department of Microbiology & Immunology, Stanford University School of Medicine, Stanford, CA, USA
- 16 5. Department of Pathology and Neuropathology, University Hospital and Comprehensive Cancer Center Tübingen,
- 17 Tübingen, Germany
- 18 6. Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
- 19 7. Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA, USA.
- 20 8. Division of Thoracic and Upper Gastrointestinal Surgery, Montreal General Hospital, McGill University Health
- 21 Centre, Montreal, QC, Canada
- 22 9. Division of Pathology, McGill University Health Center, Montreal, QC, Canada
- 23 10. McGill Genome Centre and Department of Human Genetics, McGill University, Montreal, QC, Canada
- 24 11. University of Kansas Medical Center, Kansas City, KS, USA
- 25 12. Patient Advocates in Research, Danville, CA, USA.
- 26 13. National Cancer Research Institute, London, UK.
- 27 14. Nashville VA Medical Center and Section of Surgical Sciences, Department of Cell and Developmental Biology,
- 28 Epithelial Biology Center, Vanderbilt University Medical Center, Nashville, TN USA
- 29 15. Centre for Cancer Genomics and Computational Biology, Barts Cancer Institute, Barts and The London School of
- 30 Medicine and Dentistry, Queen Mary University of London, London, UK
- 31
- 32 # equal contribution
- 33 *Correspondence: sui.huang@isbscience.org, lorenzo.ferri@mcgill.ca
- 34

35 Abstract (120 WORDS)

36 Esophageal adenocarcinoma arises from Barrett's esophagus, a precancerous metaplastic replacement 37 of squamous by columnar epithelium in response to chronic inflammation. Multi-omics profiling, 38 integrating single-cell transcriptomics, extracellular matrix proteomics, tissue-mechanics and spatial 39 proteomics of 64 samples from 12 patients' paths of progression from squamous epithelium through 40 metaplasia, dysplasia to adenocarcinoma, revealed shared and patient-specific progression 41 characteristics. The classic metaplastic replacement of epithelial cells was paralleled by metaplastic 42 changes in stromal cells, ECM and tissue stiffness. Strikingly, this change in tissue state at metaplasia 43 was already accompanied by appearance of fibroblasts with characteristics of carcinoma-associated 44 fibroblasts and of an NK cell-associated immunosuppressive microenvironment. Thus, Barrett's 45 esophagus progresses as a coordinated multi-component system, supporting treatment paradigms that 46 go beyond targeting cancerous cells to incorporating stromal reprogramming.

- 47
- 48



49 INTRODUCTION

50 Esophageal cancer is the seventh most common cancer worldwide¹ and can be divided into two major 51 subtypes that constitute biologically distinct diseases: esophageal squamous cell carcinoma (ESCC), 52 observed predominantly in the upper esophagus, and esophageal adenocarcinoma (EAC), typically 53 located in the lower esophagus². These subtypes differ in etiology, epidemiology and genetic 54 characteristics. ESSC is the dominant type in much of Asia³ while EAC is the prevalent type in Western 55 countries, with a rapidly increasing incidence of currently 5-10 cases/100,000/year^{4,5}.

56 Histologically, EAC frequently displays a glandular tissue structure and genomic alterations that are indistinguishable from those of the chromosomally unstable variant of proximal gastric cancer⁶ and very 57 58 distinct from the original squamous tissue structure typical of the esophagus. Most EACs typically 59 develop from metaplasia, an adaptive change to chronic injury caused by gastro-esophageal reflux 60 (GERD) of the lower mucosa of the esophagus known as Barrett's esophagus (BE)⁷. In this metaplastic 61 adaptive response driven by chronic inflammation, native squamous epithelium of the normal 62 esophagus is replaced by a columnar epithelium with gastric and/or intestinal characteristics and mucin 63 secretion. The prevalence of BE in the general population in Western countries is estimated to be 2% 64 and is typically only diagnosed incidentally in patients with symptomatic GERD who undergo endoscopy. 65 Patients with BE have a 40-fold increased lifetime risk of developing EAC. However, only a small minority 66 of BE cases (<1% per patient/year) progress to invasive carcinoma⁸.

67

68 Recent genome-wide analyses have focused on the identification of molecular changes occurring in the 69 esophagus epithelium during the emergence of BE to address the long-standing question of the cellular origin of the metaplastic cells⁷ and characterize early genomic, extrachromosomal 9-13 and 70 transcriptomic alterations^{14,15}. However, increasing evidence suggest that stromal alterations due to 71 72 chronic injury play a central role in development of metaplasia and progression to cancer^{16–18}. 73 Therefore, it becomes paramount to investigate disease processes in the context of the whole tissue 74 rather than focusing only on one of its components, i.e., the epithelium. To this end, we performed a systematic multi-omics analysis to characterize, in depth, the concomitant changes in epithelial, 75 76 immune, and stromal cell landscape, as well as changes in composition of the extracellular matrix and 77 tissue mechanics, during progression to cancer.

78

79 Chronic inflammation due to recurrent tissue injury can perturb tissue homeostasis and thereby contribute to tumorigenesis¹⁹. Failure to restore the original tissue structure perpetuates an aberrant 80 81 regenerative response in which the parenchymal cells do not return to a normal, stably-differentiated 82 state. The tissue may enter a metaplastic state that constitutes an adaptive response. In the case of BE-83 associated EAC, the esophageal mucosa is exposed to prolonged bile salts and acid reflux, dietary 84 irritants, alcohol, and smoking and the squamous epithelia of the lower esophagus is replaced by 85 columnar gastro-intestinal epithelia. For poorly understood reasons, metaplasia, inflammation and 86 stromal reorganization also place the tissues at a higher risk for malignancy. We have examined how this 87 perturbed homeostasis may drive tumorigenesis. The multifocal nature of BE-associated EAC, repeated 88 endoscopic surveillance and surgical resection in the absence of (neo)adjuvant therapy affords an 89 unparalleled opportunity to obtain a unique cohort of patient-matched tissue samples corresponding to

90 all clinical histological/diagnostic stages (hereafter, considered the biological 'phase' of progression) that

- 91 can be captured at a single time point in a given patient.
- 92

Our simultaneous multi-omics analysis of parenchyma and stroma at the various phases of progression 93 94 of BE to EAC revealed a coordinated program of non-genetic plasticity that included the epithelium, the 95 extracellular matrix (ECM) and stroma. This change in multi-component tissue identity at the 96 metaplastic phase was accompanied by acquisition of an NK-associated immunosuppressive tissue state 97 and the appearance of fibroblasts with characteristics previously associated with malignant stroma. The 98 joint consideration of single-cell resolution and tissue level molecular profiles enabled us to link known 99 and novel molecular markers of progression to their cellular origins and to shifts in cell-type 100 composition. Together, this multi-scale integration offers a starting point for designing multi-pronged 101 stromal reprogramming as a new therapeutic modality for reverting premalignancy or preventing 102 malignant progression.

103 **RESULTS**

104 Patient Recruitment and Sample Characteristics

105 A unique cohort of patients with BE-associated esophageal EAC was prospectively recruited to 106 participate in this study. A total of 64 fresh tissue samples from 12 newly diagnosed, treatment-naive 107 patients with confirmed EAC were collected for multi-omics analysis (Figs. 1A & S1). The samples 108 encompassed inflamed squamous esophagus (>5cm proximal to apical columnar-lined mucosa), 109 suspected Barrett's metaplasia (columnar-lined mucosa), suspected dysplasia (based on high resolution 110 white light and narrow band imaging on endoscopy), and malignant tumor. In the majority of cases, we 111 also collected columnar stomach (gastric cardia) tissue. Samples were collected at the time of 112 endoscopy (5/12) or surgical resection (7/12). Histological confirmation of suspected tissue 113 diagnosis/stage (phase of progression, see below) was provided by independent analysis by two expert 114 pathologists and the samples were labeled accordingly (Methods). Patient information, sample 115 description, and histological diagnosis are provided in Table S1.

116

117 Global survey of cell types in progression from inflamed esophagus to EAC

118 Transcriptomic profiling of 64 samples collected from 12 patients with EAC by single-cell RNA 119 sequencing (scRNA-seq) captured the transcriptomes of 175,586 individual cells (Methods). This dataset 120 consisted of patient-matched samples encompassing, in various combinations, the multiple phases of BE 121 progression defined by the clinical-histological stage/diagnosis: matched "Normal" Esophagus (mNE) 122 (obtained from the inflamed squamous esophageal tissue adjacent to the lesion), Barrett's Metaplasia 123 (M), Dysplasia (D), Tumor (T), and matched "Normal" Stomach (mNS) (obtained from the columnar 124 gastric tissue adjacent to the lesion). We also collected samples diagnosed as mixed histology, i.e., with 125 more than one diagnosis as frequently observed in this multifocal disease (Fig. S1B). For example, 126 specimen M/D for patient E17 contained both metaplasia and dysplasia.

127

After preprocessing, dimension reduction and clustering (Methods), cells clustered mainly by cell type, but some patient/sample-specific variations remained despite our strictly standardized procedure for

- 130 processing live specimens (Fig. S2A). The Harmony algorithm²⁰ was therefore applied to remove such
 - 3

131 batch effects (Fig. S2B). The unsupervised cluster analysis of cells produced 40 clusters across the two 132 clinical labels, diagnostic stage (progression phase) and patient. Correlation with reference cell type transcriptomes from the Human Cell Landscape (HCL) database²¹ (Methods) provided "coarse-grained" 133 134 cell type labels for the majority of cells. Hence, the 40 clusters could be assigned to 16 readily 135 identifiable cell types. The largest group of cells comprised gastro-intestinal (GI) epithelial cells (78K 136 cells), followed by endothelial cells (17.7K), CD8 T cells (17.1K), CD4 T cells (14.3K), and fibroblasts (9.5K) 137 (Fig. 1B-C, Table S2). In the description of this study, marker genes are designated as positively 138 expressed unless explicitly annotated as negative.

139

140 The coarse-grained cell type clusters were then split into "fine-grained" categories representing 37 cell 141 subtype labels (Fig. 1D). For example, the gastro-intestinal (GI) epithelial cells marked by MUC5AC 142 expression were further divided into "functional types" (subtypes) that included goblet cells, chief cells, 143 and foveolar cells. Gastric mucus-producing cells were identified by strong expression of MUC6 (75% of 144 cells). Chief cells were identified by expression of PGC and LIPF, goblet cells through expression of MUC2, TFF3 and SPINK4 and foveolar cells with MUC1, MUC5AC and TFF1²². For metaplasia, cells 145 expressing MUC2 and CDX2 without MUC5AC were termed 'intestinal metaplasia'²³. The batch-146 147 corrected cluster analysis thus correctly prioritized cell subtype over patient and progression phase as 148 the discriminatory cluster feature. Therefore, epithelial cells from nominal dysplasia and tumor samples 149 (D, T) were intermixed with normal and metaplastic cells in each of the cell type clusters; but the D, T150 cells had on average the highest fraction of markers for cell division, consistent with the diagnostic cell 151 labels (Fig. S2 C-D). The lists of gene markers for each cell (sub)type based on statistical differential 152 expression analysis between the clusters are available in Table S3.

153

154 Transcriptome clusters during progression are predominantly determined by the epithelium

155 While single-cell transcriptomics allowed for resolving cell type heterogeneity, in order to map cell 156 populations in their entirety to the transcriptome space and derive differential gene expression between 157 progression phases, we computationally created "pseudo-bulk" transcriptomes²⁴ selectively for the 158 coarse-grained cell types of each sample (Methods). Principal Component Analyses (PCA) of pseudo-159 bulks transcriptomes that included all cell types (mimicking classical bulk RNAseq) failed to show 160 diagnostic separation (Fig. 2A, left panel). However, PCA using only epithelial cell pseudo-bulk 161 transcriptomes were able to group the various nominal histological diagnoses. Indeed, mNE samples, 162 primarily inflamed squamous esophageal epithelium, were clearly separated from M, D and T along PC2, 163 with the exception of sample E24A (Fig. 2A, middle left panel). By contrast, and as expected, the mNS 164 samples were close to the cluster of M, D and T samples, and, in particular, overlapped with the M 165 samples in PC2 dimension, consistent with the current paradigm on Barrett's origin arising from proximal migration of gastric glandular mucosa⁷, but they were still separated in PC3 (Fig. 2A, middle left 166 167 panel). Overall, the *M* and *D* samples clustered with the *T* samples (Fig. 2A).

168

The linear discrimination by PCA lessened, but still remained, when stromal (fibroblast/myofibroblasts/ endothelial) pseudo-bulk transcriptomes were used instead of epithelial cells (Fig. 2A, middle right panel). Importantly, there was an intermixing between fibroblast cells from *mNS* with those from *M*, *D*, and *T* samples, suggesting that fibroblast phenotype reflects an early shift from a squamous (esophageal) to a columnar cell context. Immune cell bulk transcriptomes did not discriminate theprogression phases as clearly as stromal cells (Fig. 2A, right panel).

175

176 Global Differential gene expression analysis reveal an immune suppressive stroma and novel 177 dysplastic markers

To identify differentially expressed genes (DEGs) between the phases of progression, we used DESeq2²⁵
and pseudo-bulk transcriptomes of the coarse-grained cell types (Table S2) (Methods). The largest group
of cells, the GI epithelium, revealed the largest number of differentially expressed genes (6874 genes)
between tissue diagnoses, followed by endothelial cells (1612 genes), fibroblasts (624 genes) and CD8 T

- 182 cells (833 genes) (Figs. 2B & S3, Table S2).
- 183

184 In pathway enrichment analysis^{26,27}, DEGs of fibroblasts, B, Natural Killer (NK) and monocyte-derived 185 cells displayed significant associations for particular pathways (Table S4). For example, fibroblast DEGs 186 were strongly enriched for the functional annotation "TGF-beta regulation of extracellular matrix" 187 (BioPlanet 2019, adj. p-value 6e-17) (Fig. 2C), supporting acquisition of a carcinoma-associated fibroblast 188 (CAF) phenotype. Notably, genes characteristic of this pathway were under-expressed in both *mNE* and 189 mNS samples compared to M, D and T samples (Table S4). Supporting pathway analysis, DEG in 190 fibroblasts (increased SMOC1, FBN2, PDE4D and PDE10A in *M* samples; increased GDF15, ANGPTL2, C2 191 in D samples; and increased MAP3K5, TMEM158, COCH, TNFSF15, F2RL2, DKK3, BHLHE40, DCBLD1, 192 ITGAV, IL11, WNT2, and FLNA in T samples) jointly point to a TGF-beta driven immunosuppressive and 193 fibrotic program.

194

Although the goal of this survey was not to weigh in on evidence for the various hypotheses on the cell of origin of BE^{28,29} our scRNAseq analysis confirmed the presence in our *M* phase samples of previously noted "mixed" phenotype (multi-lineage) epithelial cells in conjunction with this question (Fig. S3B-D), including transitional (squamous/columnar) basal progenitor cells (KRT5+/KRT7+)^{7,30} as well as the gastric/intestinal mixed-phenotype cells¹⁵.

200

201 Cell type composition changes during progression to EAC reflect a shift in tissue identity from 202 esophagus to stomach

203 DEGs between phases can result either from changes in expression of genes in individual cells or from a 204 shift in relative abundance of cell number (cell type composition change). Single cell-resolution 205 transcriptomes permit comparison of samples at the level of the relative abundance of cell types instead 206 of molecular profiles. To evaluate the discriminatory power of this higher-level feature, the similarities 207 of the fine-grained cell type proportions were used to clusters the samples (Fig. S4A). Unsupervised 208 hierarchical clustering grouped the histological phases of samples across patients. Similar to PCA 209 analysis of epithelial pseudobulk transcriptomes (Fig. 2A, middle left panel), all mNE samples clustered 210 together, separated from the majority of mNS samples (dendrogram in Fig. S4A); in between are clusters 211 of the mNS, M, D and many T samples (right portion of dendrogram in Fig. S4A). Importantly, the ratio of 212 epithelium and stromal cell abundance was a major determinant of the large clusters (simplified heat 213 map underneath the dendrogram in Suppl. Fig. S4A). This was further supported by the observation that 214 variation in gene expression was primarily driven by changes in composition of the various epithelial cell

215 types rather than gene expression (cell phenotype) change, since the principal coordinates in Fig. 2A 216 correlated with cell type proportions across samples (Fig. S4B).

217

Analysis of specific cell type proportions at each disease phase provided additional insights (Fig. S4C). Thus, *mNS* and *M* samples tended to contain fewer immune cells. Conversely, the *T* samples exhibited a significantly higher proportion of macrophages (1.9-fold) and T cells (1.5-fold) compared to mNE (Fig. S4 C-D). Interestingly, this feature further set *T* apart from *M*, a difference not exposed by bulk gene expression profiling of immune cells (Fig. 2A). Thus, cell type abundance, used as a feature for clustering, could extract gene \rightarrow *T*. As expected, we observed a decrease of tissue-specific transcripts with increasing malignancy, in line with ric patterns despite sample-specific variability.

225

226 Changes in the individual cell types and their subtypes during progression

We first examined the epithelial cells and changes of the transcriptional states with progression (*mNE*, *mNS*) \rightarrow *M* \rightarrow *D* either differentiation arrest or dedifferentiation in neoplasia which are now considered hallmarks of malignancy³¹. The loss of differentiated cells was specifically manifest in the reduction of expression of differentiation markers, e.g., MUC5AC, FCGBP, CLCA1, MUC6 and KRT20 at the transition from M to D/T (Suppl. Fig. S4E). Thus, gastric and intestinal differentiation expression programs "faded" in the development from *M* to *D* and *T* as previously observed⁷.

233

Among tumor microenvironment cells, the relative proportions of the 6 coarse-grained cell type categories and corresponding transcript profiles changed during progression (Fig. 3). Within each of these 6 groups (fibroblasts, myofibroblasts, endothelial cells, T/NK cells, myeloid cells and B/plasma cells), we also analyzed the finer-grained cell subtypes (e.g., venous, arterial, capillary and lymphatic endothelial cells) by sub-clustering these groups individually into subgroups and quantifying changes of their abundance across disease progression phases (Methods).

240

241 First, within the fibroblasts (marked by DCN and PDGFRA expression), significant changes in cell type 242 proportions were observed (Fig. 3A). Further sub-clustering fibroblasts revealed a subpopulation 243 differentially expressing APDDC1, NTM and COL6A1 that was highly abundant in *mNE* but almost absent 244 in other tissue or progression phases (cyan cluster 3, Fig. 3A). Thus, an esophagus-specific fibroblast 245 population was already lost along with the loss of squamous epithelium at the M stage. 246 Correspondingly, the replacement of squamous epithelium by columnar epithelium in BE was 247 accompanied by replacement of APDDC1, NTM and COL6A1-expressing esophagus-specific fibroblasts by 248 PXDN, F3, POSTN-expressing fibroblast subpopulations (clusters 2, 4 and 8, Fig. 3A). These fibroblast 249 subpopulations were absent in mNE but appeared in M, D and T tissues. Intriguingly, these fibroblasts 250 that were associated with progression beyond *mNE* were transcriptionally almost identical to those 251 found in matched normal stomach (mNS) samples. These fibroblasts would be considered to be CAFs 252 (absent in mNE, present in T). Yet they were not "abnormal" per se but rather represented a cellular 253 reprogramming to a state very similar to that utilized by the non-neoplastic nearby gastric tissues (*mNS*). 254 We also confirmed a previously reported subpopulation of PI16-expressing "pan-tissue" fibroblasts (cluster 0, Fig. 3A)³² that appeared to be stable across all specimens and progression phases. 255 256

257 Next, we examined the myofibroblast compartment (expressing ACTA2, PDGFA and NOTCH3). We found 258 subpopulations resembling vascular smooth muscle cells (clusters 1, 3 and 4, Fig. 3B)³³, pericvte-like 259 cells characterized by COL1A1, COL4A1, RGS5 and CD36 expression (clusters 0, 5 and 6, Fig. 3B) and a 260 cell subpopulation expressing pro-inflammatory cytokines, such as CCL2, CCL19, CCL21 and CXCL12 261 (cluster 7, Fig. 3B). Proportions of these subpopulations remained stable between mNE, mNS, M and D 262 samples. The number of pericyte-like cells increased substantially in T samples (3.5-fold compared to mNE), a trend also observed in in gastric cancers³⁴. This stromal subtype however was not tumor-263 264 specific, as it was also found in all other stages albeit in relatively small amounts. While 265 neovascularization in tumor tissues produces abnormal vasculature devoid of pericytes, signaling from 266 these mural cells to endothelial cells is thought to be critical for promoting tumor angiogenesis^{35,36} and, 267 after injury, pericytes have been shown to detach from endothelial cells and transition to pro-268 tumorigenic, inflammatory myofibroblast-like cells³⁷.

269

270 Within the endothelial compartment, we identified four prominent subpopulations, corresponding to 271 arterial (compared to other endothelial subclusters, differentially expressing HEY1 and SEMA3G), venous 272 (ACKR1), capillary (VWA1, PLVAP) and lymphatic (CCL21) endothelial cells^{38–40} (Fig. 3C). Whereas all 273 subpopulations were present at each progression phase, we observed a significantly higher proportion 274 of capillary endothelial cells (EC) in T and mNS compared to mNE, again revealing a change in tissue 275 identity during EAC progression that shifts the entire tissue, as a unit, towards the phenotype of 276 matched gastric tissue (mNS) (Fig. 3C). Furthermore, the frequency of a particular subpopulation of venous endothelial cells (VEC, cluster 2, Fig. 3C) and lymphatic endothelial cells were also lower in T and 277 278 in adjacent mNS. VEC are the cellular source for capillary endothelium during angiogenesis⁴¹, and their 279 reduction along with the increased number of capillary EC may reflect depletion of VEC due to ongoing 280 angiogenesis in the tumor. Similarly, the low number of lymphatic endothelial cells in T is in line with the 281 general absence of lymphatics within tumors (although tumor-marginal lymphatics are critical for lymphatic metastasis)^{42,43}. However, since these vasculature remodeling features seen in T were also 282 283 found in the non-cancerous mNS, we cannot rule out that this may reflect an intrinsic property of gastric 284 mucosa that distinguishes it from the squamous epithelium of matched normal esophagus that would 285 be co-opted during EAC progression. 286

287 Marked changes of cell type composition in the immune compartment of the tumor microenvironment 288 were revealed by single-cell transcriptomics of the various phases of progression although immune-cell 289 specific bulk transcriptomes were not a discriminatory feature (Fig. 2A, right panel). Among T cells and 290 NK cells, we identified cytotoxic T cells (CD8A), T-helper cells (CD4), T-regulatory cells (FOXP3) and 291 different subtypes of NK cells (GNLY) (Fig. 3D). Most of these subpopulations were stable across the 292 progression phases with the exception that mNS tissues had reduced levels of T-regulatory cells (cluster 293 3, Fig. 3D) and displayed slightly higher numbers of cytotoxic T cells compared to the squamous mNE. 294 Interestingly, M samples exhibited a sizable increase in NK cells, notably of the NCAM1(CD56^{high}) immunosuppressive subtype^{44,45} (cluster 5, Fig. 3D; FCGR3A, FCGR3B, NCAM1/CD56, NCR1) and a 295 296 decrease in T-helper cells (cluster 1, Fig. 3D), which jointly indicated acquisition of an 297 immunosuppressive environment in metaplasia.

bioRxiv preprint doi: https://doi.org/10.1101/2023.06.08.544265; this version posted June 11, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

In the myeloid compartment, scRNAseq readily identified macrophages (MSR1, TREM2), monocytes (VCAN, S100A8), dendritic cells (PPA1, RUNX3) and neutrophils (FCGR3B, CSF3R) (Fig. 3E). Neutrophils were abundant in both *mNE* and *mNS* samples (Fig. 3E), but their frequency was significantly lower in *D* and *T* samples. Furthermore, as mentioned, there was a significant increase (3.2-fold) in macrophages in *T* samples (Fig. 3E). The frequencies of monocytes and dendritic cells were constant across disease progression phases.

305

306 Both B (MS4A1) and Plasma (JCHAIN, IGHA1) cells were present at all disease progression phases (Fig. 307 3F). Notably, *mNE* samples showed abundant B cells but contained few plasma cells. With the onset of 308 metaplasia, the fraction of B cells decreased significantly, while the fraction of plasma cells increased 309 substantially, a finding that has been previously associated with outcome of EAC⁴⁶.

310

scRNA-seq analysis reveals large CNVs in the dysplastic phase and patient-unique clonal history of
 malignant cells

- 313 Genomic instability, manifested as copy number variants (CNVs), is a hallmark of EAC. Appearance of 314 CNVs in BE has been considered an early biomarker for progression^{10,47}. To both identify aneuploid cells
- 315 and estimate clonality, scRNA-seq reads were used to estimate CNVs in each cell⁴⁸.
- 316

317 For all scRNAseg samples, we inferred CNVs in epithelial cells using inferCNV (Methods) with matched 318 normal samples (mNE/mNS) as reference. As expected, tumor samples contained a substantial number 319 of epithelial cells with CNVs (Fig. 4A-B) not found in stromal cells (Fig. 4B). Dysplastic samples contained 320 cells with CNV profiles similar to cells from the corresponding tumor, suggesting a clonal relationship 321 between dysplasia and tumor (Fig. S5A-B). Most tumors contained one major copy number profile, 322 indicating that the cells were clonally related. No large-scale CNVs were seen in metaplastic samples. 323 Only two samples diagnosed as metaplasia exhibited small amounts CNV. However, these exceptions 324 were probably due to contamination with dysplastic and tumor cells (data not shown). Of note, any 325 small-scale CNVs in metaplasia could be undetectable given the genomic resolution limit (>10MBp) of 326 the methodology.

327

To confirm scRNAseq-inferred CNVs, we performed single-cell whole exome DNA sequencing on selected samples. Comparison of CNV profiles from E21 tumor, either inferred from scRNAseq (Fig. 4C) or obtained from the matched scDNAseq sample (Fig. 4D), revealed good agreement. Both methods detected the same major clones: the first clone was characterized by chr1.q and Chr8 copy number gain, and by chr5 deletion (red CNV cluster, Fig. 4C-D); the second clone showed copy number gains of chr7 and chr8.q and deletions of chr4 and chr8.p (green CNV cluster, Fig. 2C-D). scDNAseq did not identify a third clone (blue CNV cluster in Fig. 2C), possibly due to the limited number of cells used for scDNAseq.

335

The copy number profiles of each patient's tumor were unique and manifested as distinct transcriptional clusters of epithelial cells (color-coded clusters in Fig. 4E) which dominated the interpatient heterogeneity observed in the tumor epithelial cells. In summary, our observations showed that in our small cohort, large-scale copy number variation arose at the dysplastic phase, consistent with previous findings^{10,49,50}.

342

343 Changes in extracellular matrix (ECM) composition during progression mirror concerted epithelial and 344 stromal cell changes

345 The extracellular matrix (ECM) is central to the molecular and mechanical interaction between epithelial 346 and stromal cells. We used mass spectrometry to examine ECM composition in a subset of the 12 347 patients for whom we had single-cell transcriptomic data (Fig. 1A, see Methods), focusing on 348 comparison between mNE and T: 6 tumor samples (T) and 4 patient-matched normal esophagus 349 samples (mNE) (Fig. S1A). In the ECM-enriched material purified from these samples, 1994 protein 350 groups with at least two unique peptides were quantified by mass spectrometry, roughly half of which 351 were categorized as "extracellular" proteins. Among them 78 were core matrisome proteins and 73 352 were matrisome-associated proteins (Fig. 5A). Principal component analysis of the samples based on the 353 proteomic profiles showed separation between T and mNE samples (Fig. 5B).

354

355 Comparing pooled *T* versus *mNE* samples, we found 98 proteins with significantly altered abundances in

- the ECM-enriched extract (q-value < 0.001 and |fold change| > 1.5). 55 of them showed decreased and
- 43 increased expression in *T* compared to *m*NE (Fig. 5C). The 10 proteins with the most dramatic
- 358 changes (9 "down-regulated" and 1 "up-regulated"), as well as a 22-protein matrisomal core protein
- 359 signature, are presented in Fig. S6. The decrease in ECM protein expression during progression from
- 360 *mNE* to *T* was predominantly represented by some specific collagens, in line with the reduction in
- 361 collagen-producing fibroblasts in *M*, *D* and *T* compared to *mNE* observed in the scRNAseq dataset (Fig.
- 362 3A, fibroblast cluster 3)⁵¹. As expected, expression of keratins associated with the squamous *mNE*, also
- 363 decreased during progression to *T*. Conversely, *tumor associated* ECM had increased levels of
- 364 proteoglycans PRG2 and PRG3 as well as fibrinogens FGA, FGB and FGG (Table S6).
- 365

366 Integration of scRNAseq and proteomics reveal cellular sources of ECM protein changes

We next examined whether scRNAseq findings were consistent with those of ECM proteomic analysis for the 10 patient samples analyzed by both methods (Fig. 5D). scRNAseq could provide information about the cellular source(s) of the 98 ECM-associated proteins (Fig. 5E) with significantly altered abundance in *T* vs *mNE*. As Fig. 5D shows, relative ECM protein abundances (fold-change in *T* vs. *mNE*) for this set of proteins (Fig. 5C) correlated well with the fold changes of transcripts computed as pseudobulk expression from the equivalent patient samples (Spearman R=0.73).

373

374 Specifically, scRNAseg linked changes in protein abundances at the tissue level to shifts in specific cell 375 types/subtypes that produced them. For instance, mRNA expression of collagens 6A1, 6A2 and 6A3 was 376 reduced in T samples, a phenotype that was consistent with the loss of fibroblast subtypes that strongly 377 expressed transcripts encoding these same ECM molecules during progression (cluster 3, Fig. 3A). The 378 marked reduction in collagen 14A1 in the ECM proteomic analysis could also be explained by the 379 observed shift in fibroblast subtype fractions, as transcripts for COL14A1, while expressed in mNE 380 fibroblasts, were no longer expressed in matched normal stomach (mNS) fibroblasts, the fibroblast 381 subtype that became predominant at the M phase and subsequent D and T phase (Fibroblast clusters 2, 382 4 and 8, Fig. 3A).

384 Notable departures from the correlation between ECM proteomics and scRNAseg included fibrillin 385 (FBN1) whose protein abundance increased but whose transcript levels decreased instead. This 386 discordance might be explained by its predominant expression in adipose tissue, a tissue compartment 387 represented in the proteomic analysis but totally absent in single-cell transcriptomics because 388 adipocytes are lost during the cell dissociation process⁵². Similarly, the relatively high abundance of the 389 two proteoglycans, PRG2 and PRG3, in tumor ECM was not concordant with transcript analysis which 390 showed no expression in T and mNE. This finding is consistent with the predominant production of these 391 proteoglycans in liver and bone marrow (and in female reproductive organs) and suggest that these 392 proteins may have been deposited via circulation in the esophagus tumor stroma⁵³. Similarly, 393 fibrinogens FGA and FGB, which are solely produced in the liver, were also unexpectedly elevated in the 394 tumor ECM proteome of several patients but not in the corresponding tumor transcriptome⁵⁴, pointing 395 again to the synthesis of fibrinogen in the liver and subsequent deposition at the tumor site. Strikingly, 396 concordance between fibrinogen proteome and transcriptome was observed for one patient (E14). This 397 concordance between fibrinogen protein and local transcripts could be explained by the rare but 398 previously reported occurrence of hepatoid differentiation (documented by identification of an alfa-399 fetoprotein (AFP)-expressing cluster) of the EAC of this patient.

400

401 Examining cellular sources confirmed that one major protein absent in the tumor ECM-enriched extract, 402 KRT13 (Fig. 5C, Suppl. Table S6), a keratin filament protein characteristic of stratified squamous 403 epithelium, resulted from the replacement of the esophagus squamous epithelium by a gastro-intestinal 404 columnar epithelium (Fig. 5E). Another protein of interest was periostin (POSTN), an ECM protein that 405 was moderately but significantly increased in the tumor ECM (Fig. 5C, Table S6). Cell-type specific 406 transcript analysis (Fig. 3A) had shown that it was a prominent marker of a subtype of fibroblasts 407 associated with gastric tissue, and characteristic of progression from mNE to M, D, and T (fibroblast 408 clusters 2, 4 and 8, Fig. 3A). Tumor transcript analysis in the pseudo-bulk data (Fig. 5D) failed to detect 409 an increase in transcripts of POSTN in this comparison, although it has been previously implicated in 410 BE^{15,55}. However, single cell-resolution analysis showed that, while POSTN transcripts were elevated by 411 almost two-fold in tumor-associated fibroblasts, in this same sample set, the tumor capillary endothelial 412 cells (Fig. 3C), showed instead a down-regulation of POSTN by more than two-fold (Fig. S7A-B). Thus, a 413 shift of transcript levels for a given gene in opposite directions in distinct cell types/subpopulations 414 might conceal differential expression in bulk RNAseq (Fig. S7A-B).

415

Finally, among the most significantly increased non-ECM proteins in the ECM-enriched preparation of T compared to mNE samples (Table S6), were Ig-related subunit chains IGHA2 and IGKC (Fig. 5C). This increase could readily be attributed to the surge of plasma cells in *T* compared to *mNE*, consistent with the cell-type composition changes noted above (Fig. 3E)^{46,56,57}.

420

Taken together, scRNAseq and cell type-level resolution analysis not only allowed us to trace back the cellular origin of changes observed in bulk analysis methods, such as proteomics, but also allowed us to expose opposing expression changes in distinct cell type compartments that might have masked a celltype specific differential expression.

426 Changes in mechanical stiffness during progression confirm concerted epithelial and stromal 427 alterations

Since ECM changes have been linked to altered mechanical tissue stiffness, which in turn can affect tumor-promoting signaling⁵⁸, we used atomic force microscopy (AFM) to assess the stiffness of esophageal tissues during disease progression by comparing AFM characteristics of samples across disease progression phases for epithelial and stromal stiffness (Fig. S8A-B). Stiffness measurements of epithelium were found to be in a range similar to those previously published (0.6-3.0 kPa)^{58–60} (Fig. 5F). Strikingly, stiffness of the *mNE* (squamous) epithelium was ~20-times higher than that of *mNS* (columnar) epithelium (1.2 vs. 0.06 kPa).

435

436 Metaplastic Barrett's esophagus (M) not only acquired a gastric histology but also a "softer" gastric-like 437 stiffness. However, as expected, this lower gastric-like stiffness increased with pathological progression. 438 Although the stiffness of epithelia in the columnar lesions M, D, T was 3-8 times lower (0.15, 0.4 and 439 0.45 kPa, respectively) compared to that of the squamous mNE, stiffness of these gastric-like columnar 440 lesions was still 3-8 times higher than that of normal tissue, mNS (Fig. 5F). Thus, while the esophageal 441 columnar lesions adopted a softer gastric-like identity, their stiffness was still significantly higher than 442 that of the non-cancerous mNS. This observation is in accordance with the well-documented general 443 concept of increased stiffness in diseased/cancer tissue compared to healthy tissue⁶¹.

444

445 AFM analysis also revealed mechanical changes in the stroma. Consistent with the difference in 446 epithelial type, stiffness of the stroma of mNE esophagus (~0.6 kPa) was dramatically higher than that of 447 mNS (~0.04 kPa) (Fig. 5F). However, in most samples, the stroma of the columnar lesions M, D, T was 448 similar or only slightly softer than that of *mNE* (0.24-0.26 kPa vs. 0.6 kPa), with large variation between 449 samples; some regions exhibited much higher stiffness, reflecting the general trend of neoplastic tissues 450 (Fig. 5F). The moderate decrease in stromal stiffness that correlates with replacement of squamous by 451 columnar tissue during progression was in accordance with the observed decrease in ECM proteins, such 452 as laminin and prolargin, as well as stromal cell cytoskeletal proteins that link cell mechanics to the ECM 453 (e.g. desmin, calponin, dystrophin, and filamins A and C), as identified by the ECM proteomics (Table S6). 454

455 Multiplexed protein imaging reveals reorganization multi-cellular tissue neighborhood during 456 progression

457 To interrogate the spatial relationships of the cell types within the progression phase of EAC, we 458 performed CODEX multiplexed protein imaging on 27 imaging regions in the esophageal tissue from 5 of the 12 patients (Fig. 6A, Fig. S9A)^{62–64}. Diagnosis of tissue and phase of progression (*mNE*, *M*, *D*, *T*; *mNS*) 459 460 was verified by pathologists with regard to proportions of cells using H&E (hematoxylin and eosin) 461 staining of the same sections post-CODEX (Fig. S9B-D, Table S8). Given our focus on stroma, we designed 462 our 54-antibody panel to interrogate epithelial, stromal and immune cell types (Table S9). The CODEX 463 marker panel allowed us to identify 45 unique cell types (Fig. S9E), 25 of which were epithelial⁷, 464 including "squamous" (*mNE*), "foveolar" (*M*), p53+ (p53-expressing) and lineage-negative epithelial cells 465 (D, T) (Fig. 6B,E, Fig. S9F), which were consistent with the overall change in cell type proportions seen in 466 the scRNAseq (Fig. S10).

468 Because CODEX preserves tissue geography, we next asked if spatial proximity of cell types to one 469 another was altered during disease progression in light of the dramatic changes in cell type composition observed by scRNAseq (Figs. 2 and 3). Thus, we performed cellular neighborhood (NH) analysis to 470 identify conserved multicellular microstructures (Methods)⁶⁵ and expose changes in tissue organization 471 472 not observable by shifts in global cell proportions using scRNAseq. We identified 24 unique multicellular 473 neighborhoods that were labeled based on enrichment of cell types within each neighborhood (Figs. 6C 474 and S11A-B). For example, as expected, *mNE* samples were highly enriched for an "apical squamous" NH 475 - characterized by Annexin A1+ squamous cells - and for a "basal squamous" NH - characterized by both 476 Annexin A1+ and p63+ squamous cells (Fig. S11C,D).

477

478 We also detected a NH enriched for foveolar and goblet cells (Fig. S11B, F-G) that we termed 479 "specialized" NH, consistent with previously defined gland phenotypes in metaplasia⁶⁶. As expected, this 480 "specialized" NH correlated with the percentage of metaplastic epithelium (Fig. 6D, Fig. S12A). We also 481 detected NHs that were consistent with known epithelial organization (e.g., "mature intestinal" NH, 482 "oxynto-cardiac" NH, "atrophic cardiac" NH). In addition, we identified novel conserved NHs (e.g., 483 "muc5low specialized" NH, "muc6low mature intestinal" NH) characteristic of BE epithelial organizations 484 (Figs. S12A and S13A). Analysis of neighborhoods allowed us to assign specific molecular alterations of 485 malignant cells to this higher-level pattern of tissue organization. For instance, the "p53hi atrophic 486 cardiac" NH correlated with the proportion of metaplastic epithelium, attributing p53 expression to 487 particular glands (Figs. S12A and S13A).

488

In the stroma, we identified several consistent neighborhood organizations (e.g., a "stroma and immune" NH, a "stroma and neutrophil" NH, and a "follicle, smooth muscle, vasculature" NH).
Interestingly, presence of the "stroma and neutrophil" NH correlated with the proportion of epithelium classified independently as high-grade dysplasia by two expert pathologists across all samples (Fig. S11E). This NH also was enriched for CD4+ T cells, lymphatic and vascular endothelial cells, and antigen-presenting cells (Fig. S11B).

495

496 Communities of cell neighborhoods illustrate rearrangements of epithelial-stromal cellular entities 497 during progression

498 Multiple NHs correlating with the specific histological phase of BE progression (M, D) suggested that the 499 size of an effective cellular neighborhood structure was smaller than the larger overall pathology that 500 underlies the histological diagnosis. This feature is reflected in the unique NH calls for cells of a single 501 gland and in the local stromal NHs for a given histological pathology (Fig. 6E). To better align 502 multicellular structures to the overall histological diagnosis, we thus evaluated the co-localization of 503 multiple NHs, referred to as "communities" (of neighborhoods). We defined specific communities of NHs 504 by increasing the number of neighborhood-defining cells (100), using the NH labels as input⁶⁷. This 505 process revealed a total of 10 unique communities (C) of neighborhoods (Fig. S12B-C). Thus, the "apical 506 squamous" NH and "basal squamous" NH were found within a single "squamous epithelial community 507 (C)" because of their characteristic occurrence in proximity to each other (Figs. 6F & S12B). The presence 508 of the "squamous epithelial C" correlated across all samples with the percentage of squamous 509 epithelium (Fig. 6G). Three other communities of NH showed positive correlations with the proportion

510 of epithelium: *"Specialized and Mature Intestinal C"* with M, *"Inflamed Dysplasia C"* with D and 511 *"inflamed mature intestinal C"* with T (Fig. 6G).

512

513 The relationship of community structures with the phases of progression afforded a new looking glass 514 for considering tissue geography in the cellular changes associated with BE progression by analyzing 515 cellular composition of communities instead of the global composition as captured by scRNAseq (Fig. 516 6H-J, Table S10). Overall, this analysis revealed an increase in immune and mesenchymal cells in the 517 communities with progression.

518

519 Within the epithelial cell compartment, with progression the squamous cell community (*"squamous epithelial C"*) yielded to the foveolar community (*"Specialized and Mature Intestinal C"*) that increased in 521 epithelial cells that were negative for squamous and metaplastic lineage markers (Figs. 6H, S9E & S12D) 522 reflecting changes both at the level of glandular structures, towards gastro-intestinal formations, as well as loss of cellular differentiation associated with progression.

524

525 Within the immune cell compartment, the proportion of neutrophils increased within the "inflamed 526 dysplasia C" (Figs. 61 & S12E). Indeed, three of the neutrophil-enriched NHs were specifically enriched 527 within the "inflamed dysplasia C" (Fig. S12F). Strikingly, while most immune cell types also increased 528 within the "inflamed mature intestinal C", which correlated with invasive epithelium or tumor 529 pathology, neutrophils did not. Instead, macrophage subsets were enriched (Figs. 6I & S12G). This 530 "inflamed mature intestinal C" was enriched with diverse NHs, namely the "mature intestinal and 531 immune" NH, the "APC enriched immune" NH, and the "stroma and immune NH" (Fig. S11B). Each of these NHs were characterized by abundance of immune cells (e.g., CD4+ T cells, macrophages, DCs, 532 533 CD8+ T cells) and absence of neutrophils. Finally, in this "inflamed mature intestinal C", the proportion 534 of CD4+ Tregs also increased (Figs. 6I, S12I & S13H). This trend may reflect the role of Tregs in 535 preventing neutrophil accumulation during tissue repair⁶⁸.

536

537 Analysis of mesenchymal cells in communities revealed that the CD36hi endothelial cell population was 538 robust in the "specialized & mature intestinal C" (associated with metaplasia) but reduced in the 539 "inflamed dysplasia C" and "inflamed mature intestinal C" (Fig. 6J). Interestingly, the abundance of 540 CD36hi endothelial cells within all samples negatively correlated with the abundance of CD4+ Tregs (Fig. 541 S12J). This negative correlation was in accordance with the opposite phenotypes of a CD36hi anti-542 tumorigenic state and a CD4+ Treg high immunosuppressive, pro-tumorigenic state. This finding 543 underscores the added value of evaluating cell proportion changes with structural guidance of cell 544 communities and is consistent with the downregulation of CD36 in chronically-inflamed tumor stroma⁶⁹. 545

546 Cell type combinations in cell-cell interactions in stroma reprogramming during progression

547 We next exploited the spatial NH information to examine cell-cell interactions (Figs. 6K & S13A-C, Table 548 S11). To evaluate the enrichment of cell-cell interactions in particular progression phases (*M*, *D*, and *T*), 549 we calculated the frequency of neighbors using a nearest neighbor approach and compared the 550 frequency of occurrences to null-models, achieved by 10,000 permutations of cell type locations 551 (Methods). Cell-cell interactions shared by all phases included those between immune cells (CD8+ T cell, 552 "M1" macrophage, and plasma cell) and stroma cells (Fig. S13D). This was consistent with the increase in 553 plasma cells across all disease phases observed with CODEX (Fig. S13E) and scRNAseq (Fig. 3F). Plasma 554 cells are normally seen within mucosal areas of the intestine and form a conserved niche⁶⁷. Thus, the 555 increase in plasma cells (Fig. 6I) and the identification of a specific "plasma cell enriched" NH (Fig. S11B) 556 may represent an aspect of reprogramming of the stromal environment.

557

558 Many unique interactions involving foveolar cell type were enriched in BE (Fig. 6K). For instance, in M, 559 but not D or T samples, foveolar cells were found next to the CD36hi endothelial cells and to nerves 560 (Figs. 6K-L & S13F), in line with their enrichment within the "specialized & mature intestinal C" (Fig. 6I). 561 Additionally, in both M and D, foveolar cells were found close to CD4+ T cells and plasma cells (Figs. 6M-562 N & S13G-H), consistent with plasma cell niches known to accompany intestinal epithelial transitions. 563 Finally, we observed that neutrophils paired with lymphatic cells, endothelial cells and M1 macrophages 564 in D and T (Figs. 5M-N & S13I).

565

566 Epithelial and stromal cellular communities become increasingly diverse during progression

567 Communities associated with BE progression had altered proportions of both epithelial and stromal cell 568 types (Figs. 6H-J & S12C-G, Table S10). Indeed, the diversity of gland structures has been shown to be associated with progression in BE⁷⁰. However, our analysis also took into account the stromal 569 570 component. We quantified the diversity of cell types in communities using the CODEX markers (Fig. 60) 571 and found an increase in Shannon's diversity index H in the communities associated with progression: 572 H("squamous epithelial C") < H("specialized & mature intestinal C") < H("inflamed dysplasia C") <573 H("inflamed mature intestinal C") (Fig. 6O). This pattern indicated that areas with high (chronic) 574 inflammation and lacking well-differentiated structures were more likely associated with invasive 575 tumors.

DISCUSSION 576

577 In this study, we describe concomitant epithelial and stromal changes occurring during progression from 578 a premaligant state (BE) to invasive cancer (EAC). This was made possible by analyzing 64 tissue samples 579 collected from 12 individual patients that represent the sequential histological phases of BE progression 580 from matched "normal" esophageal tissue (mNE), to Barrett's metaplasia (M), dysplasia (D) and invasive 581 adenocarcinoma (T) in the same patients. The matched normal stomach tissue (mNS) constituted a key 582 reference because BE is the adaptive acquisition of a gastric/intestinal-like tissue. The disease 583 progression phases co-occur within the same patient and thus can, to some extent, be regarded as a 584 progression trajectory. Our data show marked phase-specific alterations shared by the twelve patients 585 at multiple size scales, with respect to transcriptome, cellular content, large-scale CNVs, ECM proteomic 586 profile, tissue mechanics, and histological architecture, with some patient-specific variability. Our 587 studies underscore the importance and highlight new opportunities of not only multi-omics but also 588 multi-scale integrated analysis.

589

590 A major insight is that, despite absence of obvious histological alteration in the stromal compartment, 591 the stroma also underwent, from early in progression (M phase), drastic changes in cellular, mechanical 592 and molecular identity and tissue organization that complemented those seen in the epithelium. The 593 multi-scale approach enabled a combined assessment of change at the levels of cell numbers (cell type 14 594 proportions) and cell states (molecular cell subtype) which affected epithelial cells, fibroblasts, 595 endothelial cells, immune cells, acting in concert during advancement to malignancy and revealed wide-596 spread and coordinated non-genetic cell plasticity.

597

598 A key finding was the early loss of esophagus-type and gain of gastric-type fibroblast subpopulations 599 with onset of epithelial metaplasia (BE) and in ensuing progression. Thus, the epithelial change from 600 squamous to columnar (mNE \rightarrow M) was accompanied by a commensurate transition from squamous-601 supporting fibroblasts to columnar-supporting fibroblasts (Fig. 3A); this shift was robust enough to 602 separate mNE from mNS/M/D/T in PCA space based on pseudo-bulk transcriptomes of stromal cells (Fig. 603 2A). This result is consistent with concerted changes of epithelium and stroma as one unit in the tissue 604 trajectory of healthy to premalignant and malignant tissue. Besides acquiring a gastric identity upon 605 transition to M and later to D and T, these fibroblasts also acquired characteristics previously 606 documented in carcinoma-associated fibroblast (CAF) populations, i.e., expression of TGF-beta targets⁷¹. 607 Most investigators believe that tumor cells program fibroblasts into pro-tumorigenic CAFs. However, 608 substantial data suggest that pro-tumorigenic fibroblasts may already be present before development of a tumor^{69,72}. Our analysis of these esophageal samples at single-cell resolution confirmed this 609 610 observation. The origin of these pro-tumorigenic fibroblasts is intensely speculated. The presence of 611 pro-tumorigenic fibroblasts in BE may simply reflect the outgrowth of gastric tissue as one epithelium-612 stromal unit or it may involve the migration of gastric fibroblasts. Alternatively, presence of the latter 613 may reflect a cell-level state transition (i.e., transdifferentiation) of local esophageal fibroblasts originally 614 supporting the squamous epithelium during progression or a reprogramming of progenitor (fibroblast) 615 cells. Finally, recent studies have demonstrated the transition of injured pericytes to a CAF-like state 616 that are pro-tumorigenic³⁷.

617

618 The shift in fibroblast subpopulation occurred early at the $mNE \rightarrow M$ transition (Fig. 3A). This might 619 entertain the interpretation that stromal changes precede and possibly drive epithelial transformation 620 to malignancy⁷³. Ongoing analyses on patients diagnosed with BE but who, unlike the patients in his 621 study, have not progressed to dysplasia or carcinoma will allow us to discriminate between events 622 already occurring at the BE disease phase in the absence of malignancy from events occurring in a BE 623 which has been subjected to a potential tissue field effect by the neighboring tumor. It should also be 624 noted that tissue plasticity described at these early stages of disease occurs in the absence of major 625 mutational or genomic alterations and thus represent examples of non-genetic plasticity in all tissue 626 components.

627

628 To more explicitly demonstrate the added value of single-cell resolution compared to bulk (whole 629 sample) analysis and explore a multi-scale analysis, we generated pseudo-bulk transcriptomes from the 630 scRNAseg data and compared samples as wholes or selectively, with respect to specific cell types. This 631 analysis showed that, at the whole tissue level, clustering of histology-based diagnosis (disease phases) 632 and corresponding disease progression phases was most obviously associated with changes in the 633 epithelium. However, extending previous reports emphasizing the role of stromal and immune cells in 634 tumor progression, our study shows that single-cell resolution, let alone the cells' spatial configuration, 635 must also be considered for discriminating disease phases and courses. 636

637 Analysis of ECM-enriched proteins with progression to tumor was in great part accompanied by 638 corresponding gene expression changes in epithelial and stromal cells. Integration with scRNAseq 639 pinpointed the cellular source down to the granularity of sub-cell types. The increased transcript 640 expression in M, D, T fibroblasts of periostin (POSTN), a developmental ECM protein overexpressed in 641 many tumors⁷⁴, was also increased in the ECM-enriched proteome of T samples compared to mNE (Fig. 642 5C). The scRNAseq data (Figs. 3A and 5E) readily attributed its source to the particular subpopulations of 643 fibroblasts that were shared by matched normal gastric samples (mNS). Interestingly, this change of 644 expression was partially compensated by a decrease in expression by endothelial cells at more advanced 645 phases of progression (Fig. S7A-B).

646

647 Similarly, the marked decrease in expression of some types of collagens in EAC tissues was in accordance 648 with a shift in the subtype of fibroblasts associated with T compared to those in *mNE* samples (Fig. 5A). 649 The granular cell-type level resolution of our analyses allowed us to fully appreciate the complexity of 650 such stromal changes, underscoring the importance of the specific cellular source for a change in 651 abundance of a protein in the bulk tissue. Thus, despite the net decrease in collagen-6 protein that could 652 be attributed to a loss of squamous epithelium-associated fibroblasts, this decrease was accompanied 653 by selective increased transcript expression in myofibroblasts (Fig. S7A). This apparent discordance 654 epitomizes the concerted changes in multiple cell types that converge to a pro-tumorigenic tissue 655 landscape. Indeed, whereas COL6-deficient fibroblasts would no longer assemble and maintain a 656 homeostatic ECM, the collagen-6-expressing myofibroblasts would instead drive inflammation and fibrosis via endotrophin, the proteolytic bioactive product of collagen 675,76. These COL6-positive 657 658 myofibroblasts would correspond to the previously described dermoplastic fibroblasts found in 659 melanoma⁷⁷ and BE¹⁵. 660

661 The molecular changes in ECM and cells observed during progression was also manifest in the parallel 662 alteration of mechanical properties of both epithelium and stroma. The reduced epithelium stiffness 663 associated with the switch from squamous to gastric tissue is in agreement with the reported 664 progressive decrease in AFM stiffness in metaplastic CP-A (3.1 kPa) and dysplastic CP-D (2.6 kPa) 665 esophageal epithelial cell lines compared to that of the squamous esophageal epithelial EPC2 cell line 666 $(4.7 \text{ kPa})^{78}$, but also in the stroma albeit to a lesser more varied extent. However, progression from M to 667 T still kept the tissue stiffer than that of inherently softer non-cancerous mNS gastric tissue (Fig. 5F), in 668 line with the often observed increase in tissue stiffness in malignancies, which in turn feeds back to 669 modulation of gene expression, including genes that control ECM composition. This mutualism between 670 cellular programs and tissue mechanics underscores the importance of joint analysis of molecular, 671 cellular and mechanical changes^{78,79}.

672

Our study also highlighted the importance of considering cell (sub)type abundances as quantitative observables (Fig. 3), illustrated by: (i) the gain of a gastric-specific fibroblast population (Fig. 3A, clusters 2 and 4) at the expense of an esophagus-specific fibroblast population (Fig. 3A, cluster 3) discussed above; (*ii*) a dramatic over-representation of pericyte-like cells (Fig. 3B, clusters 0. 5 and 6) occurring late, i.e. only at the tumor stage; (*iii*) a similar delayed over-representation of VWA1 and PLVAPexpressing endothelial cells (Fig. 3D, cluster 0), two ECM proteins involved in the formation of the stomatal and fenestral diaphragms of blood vessels; (iv) an early and drastic decrease in neutrophils expressing genes of phagocytic and bactericidal function (Fig. 3E, clusters 3 and 7); and (v) a drastic loss
of B cell predominance over plasma cells seen in *mNE* but not in *mNS*, and at all phases of progression
(*M*, *D*, *T*) (Fig. 3F).

683

684 The combined analysis at various size scales of tissue geography enabled by CODEX afforded a new lens 685 through which hitherto unseen tissue organizational changes during progression become visible (Fig. 686 6P). The identification of consistent cell neighborhoods (NH) and communities (C) of NHs allowed us to quantify changes in the number of cells of particular types (e.g., POSTN^{hi} fibroblasts, CD36^{hi} endothelial 687 688 cells, p53+ epithelial states) within distinct structures, exposing differentials lost by averaging over large 689 areas. In addition, these structures themselves change in number with progression. For instance, the 690 reduction in neutrophils and concomitant increase in Tregs within the same cell community during EAC 691 progression could not be detected at the global tissue level by scRNAseq. Such changes are of high 692 biological significance, given that the role of Tregs in tissue repair is in part mediated by suppression of 693 neutrophils⁸⁰. The identification of specific multicellular neighborhoods in metaplastic epithelium was 694 consistent with previous descriptions of distinct glandular structures found within BE⁷⁰.

695

696 Shifts in cell state during disease progression from *mNE* to EAC revealed the establishment of an 697 immunosuppressive tumor microenvironment permissive for malignant progression^{81,82} 698 Aforementioned POSTN expression, first appearing in M fibroblasts has been proposed to serve as a 699 biomarker for BE progression⁵⁵ and is implicated in immunosuppression in the TME⁸³. Furthermore, 700 other highly differentially expressed genes in the POSTN-expressing fibroblast cluster associated with M. D. T included CXCL14, also recently reported in BE scRNAseg analysis¹⁵. Notably, CXCL14 has been 701 702 reported to exert immunosuppressive activities when secreted by fibroblasts but not by epithelial 703 cells⁸⁴. POSTN and CXCL14 expression may contribute to the local enrichment in Tregs observed in some 704 CODEX cell neighborhoods of D and T samples. For instance, the "inflamed mature intestinal" 705 community which increased in number in T samples, contained numerous CD4 Treg cells. Similarly, 706 through consideration of neighborhood structure we found a negative correlation between Tregs and 707 CD36hi endothelial cells in some neighborhoods regardless of the disease phase, in line with the 708 reported association of loss of CD36hi endothelial cells with increased risk of progression in breast cancer^{69,72}. 709

710

711 At the level of specific genes and pathways associated with EAC progression, numerous inflammatory 712 and malignancy markers in fibroblasts appeared in all modalities: scRNAseq, ECM proteomics and 713 CODEX. Overall, as expected, fibroblasts with gene signatures such as "TGF-beta regulation of 714 extracellular matrix", or "Collagen biosynthesis and modifying enzymes", were enriched with 715 progression as early as metaplasia, in line with adaptive alterations of a stroma subjected to the 716 constant stress of chronic inflammation. Specific changes pointed to a loss of tissue homeostasis 717 involving ECM remodeling by matrix metalloproteinases and collagen chaperones, such as SERPINH1, 718 ultimately resulting in the uncontrolled release of cytokines, such as TGF-beta. Such unopposed TGF-719 beta signaling might account for the upregulation of periostin expression in fibroblasts at the metaplastic phase^{15,85}. 720

722 Finally, the traditional use of systematic molecular profiling and differential expression/abundance 723 analysis remains potentially useful, notably if we exploit the availability of samples in the progression 724 phases. The identification of a small panel of biomarkers (PRAME, MAGEA6, CASP10, PTPN12, and 725 FAM183A) specifically upregulated at the dysplasia stage (D) is of particular practical importance 726 because they could serve as a much sought after biomarker panel for the rare progression from 727 premalignancy (BE) to malignancy (EAC). If confirmed, such biomarkers could initiate and justify more 728 aggressive ablative treatments in any dysplastic BE (including low grade dysplasia) prior to invasive 729 malignancy.

730

731 This Atlas of BE progressing to EAC, offers multiple modalities of data that also span multiple size scales 732 from molecular profiles to tissue architecture and mechanics, and will serve as a valuable resource to 733 the research community. Two limitations of this study are: (1) the course of progression is inferred from 734 snapshots of metachronic parallel evolution of lesions as a surrogate of a time course (longitudinal 735 monitoring), which however is permissive given the established sequence of the phases of progression; 736 (2) our matched normal samples used as non-cancerous baseline are actually not disease-free but likely 737 already inflammed tissues as revealed by comparison to disease-free individuals (unpublished 738 observations). Interactive web-portals to interrogate specific molecules in specific cell type and 739 progression phase are available (Methods). Many descriptive but intriguing findings await experimental 740 examination or focused validation in larger cohorts. Clinical translation of some of the observed changes 741 into actionable biomarkers for risk stratification or targets for prevention and intervention holds 742 tremendous potential. It will be also of great interest to determine if our findings can be extended to 743 other chronic inflammation-driven malignancies.

744 METHODS

745 Sample Collection, Preparation, and Measurements

746 Human Barrett's Esophagus Tissue Specimens

747 Fresh tissue specimens were obtained from consented patients with treatment naive Barrett's 748 esophageal adenocarcinoma (Research Institute - McGill University Health Centre REB # 2007-856) 749 undergoing endoscopy or esophagectomy. They were collected from regions containing tumor, matched 750 normal gastric (gastric cardia) and/or esophageal mucosa (at least 5 cm proximal to the top of columnar 751 lined mucosa), suspected metaplasia and suspected dysplasia. High-Definition white light and narrow 752 band endoscopic imaging was employed to attempt to clinically differentiate dysplasia from non-753 dysplastic columnar lined mucosa (Barrett's metaplasia) at the time of surgery. Only tissue specimens 754 with confirmed histological diagnosis were used in subsequent multi-omic analyses (e.g. single cell 755 transcriptomics, multiplex imaging, ECM proteomics). Histological diagnosis was performed on H&E 756 stained sections of formalin fixed paraffin tissue blocks and corroborated by consensus of two expert 757 pathologists (S.C.-B. And P.-O.F.). Collected tissue specimens were divided in equal sections and placed 758 in cold medium (RPMI (Invitrogen) supplemented with Primocin (Invivogen) and gentamycin 759 (Invitrogen)) for single cell RNA sequence processing or shipment to various sites for subsequent 760 analyses. Patient demographics, exposure history (e.g., smoking, proton inhibitor use), Barrett's extent 761 (Prague Classification), and tumor characteristics (grade, stage) were collected (Suppl. Fig S1A).

763 Single-cell RNAseq Methods

764 Single cell dissociation

765 Tissue specimens were dissected to remove necrotic areas, minced and digested in 5 mL of Advanced 766 DMEM/F12 containing 10 mg Collagenase Type 3 (Worthington) and 500 U Hyaluronidase (Sigma) in a C-767 tube (Miltenyi) using the gentleMACS Octo Dissociator (Miltenyi). The single cell suspension was 768 resuspended in PBS and 1mM DTT, strained through a 100um cell strainer (Fisher) and spun down 769 (500xg, 5 minutes, 4°C). Cells were resuspended in 0.25% Trypsin-EDTA (Invitrogen) and incubated for 5 770 minutes at 37°C, followed by addition of 10% fetal bovine serum to inactivate trypsin. The cell pellet 771 (500xg, 5 minutes, 4°C) was resuspended in 2.5U Dispase/10ug DNAse buffer and incubated for 5 772 minutes at 37°C. The buffer was inactivated by adding excess PBS and the homogenate was strained (40 773 uM, Fisher) prior to centrifugation (500xg, 5 minutes, 4°C). Red blood cells were lysed using ACK Lysing 774 Buffer (Gibco) for 5 minutes at room temperature, followed by addition of excess PBS, prior to 775 centrifugation (500xg, 5 minutes, 4°C). The cell pellet was finally washed twice with 2% fetal bovine 776 serum in PBS prior to proceeding with single cell capture on the 10x Genomics platform.

777 Single cell suspension quality assessment

Before credentialing the cell suspension, the cells were filtered through a 40 um FLOWMI cell strainer (SP Bel-Art; H13680-0040). Whenever necessary, centrifugation of the cells was carried out at 300xg for 11 minutes. Single cell viability and presence of debris and erythrocytes in the single cell suspension were assessed prior to single cell capturing. Upon adequate viability (i.e. lack of debris and erythrocytes), cells were captured on the 10x Genomics platform.

783 Cell viability was tested using the "LIVE/DEAD Viability/Cytotoxicity Kit for mammalian cells" that 784 contained Ethidium Homodimer-1 and Calcein-AM stain (ThermoFisher ; L-3224) dyes. First, a viability 785 stain mix was reconstituted by mixing 0.5 ul of 4mM Calcein-AM, 2ul of 2mM Ethidium Homodimer-1 786 and 100ul of PBS. A 5ul of cell suspension was then resuspended in 5ul of viability stain mix and the 787 solution was incubated at room temperature for 10 minutes. The sample viability was verified using a 788 hemocytometer (INCYTO C-Chip; DHC-N01-5) through GFP (for the Calcein-AM) and RFP (for the 789 Ethidium Homodimer-1) channels on an EVOS FL Auto Fluorescent microscope (ThermoFisher). Viability 790 was expressed as the percentage of live cells (Calcein-AM / GFP positive cells) over the sum of live 791 (Calcein-AM / GFP positive cells) and dead cells (Ethidium Homodimer-1 / RFP positive) cells.

792 Erythrocyte contamination was assessed by staining the cells with the cell permeable DNA dye DRAQ5 793 (ThermoFisher ; 65-0880-92). A nuclear staining mix was made by diluting the DRAQ5 stock solution 794 (5mM) down to 5uM with 1x PBS. Afterwards, 5ul of cell suspension was re-suspended in 5ul of nuclear 795 stain mix and the solution was incubated at room temperature for 5 minutes. The nuclear stain was 796 visualized using a hemocytometer (INCYTO C-Chip; DHC-N01-5) through the Cy5 channel on an EVOS FL 797 Auto Fluorescent microscope (ThermoFisher). Erythrocyte contamination was expressed as the 798 percentage of "round donut-shaped DRAQ5 negative objects on bright-field" over the sum of "round 799 donut-shaped DRAQ5 negative objects on bright-field" and "nuclear stained DRAQ5 positive cells".

Additionally, we assessed the cell suspension for the presence of any other contaminants/debris as well as contaminants that might interfere with the capturing on the microfluidic chip such as large debris.

802 The percentage of debris presented in the sample was expressed as follows: Percentage of "observed

803 non-cell objects on bright-field" over the sum of "observed objects on bright-field" and "observed cells 804 marked on the fluorescent channels". A sample was deemed adequate for capturing if "cell viability" 805 was \geq 70%, "erythrocyte contamination" was \leq 10% and "debris percentage" was \leq 30%. The cell 806 concentration in the cell suspension, measured by counting the number of "Calcein-AM / GFP positive 807 cells" and "Ethidium Homodimer-1 / RFP positive cells" in the large 4 squares on each corner of the hemocytometer, was calculated as follows: Number of cells / ul =[(Calcein-AM / GFP positive cells + 808 809 Ethidium Homodimer-1 / RFP positive cells) / 4] * 10 * 2 where 10 was the dilution factor on the 810 hematocytometer and 2 was the dilution factor when the cell suspension was mixed with the dye 811 solution.

812 Single cell capturing

Single cells were captured on the 10x Genomics platform. Single cell 3' end gene expression profiling was carried out according to the "Chromium Next GEM Single Cell 3' Reagent Kits v3.1" protocol and recommended reagents. Single cell Copy Number Variation was queried using the "Chromium Single Cell DNA Reagent Kits" protocol and recommended reagents. Of note the CNV kit described above is

- 817 currently discontinued. The sequencing libraries were created as per the above protocols with the
- 818 modifications presented in the following section.

819 Sequencing of the 10x single cell libraries

- 820 Libraries were quantified using a LightCycler 480 Real Time PCR instrument (Roche) and the KAPA library
- quantification kit (Roche) with triplicate measurements. Library quantification values were used both forthe MGI library conversion and for Illumina sequencing normalization.
- 823 Libraries sequenced on MGI (MGI Tech) were converted after 10x library construction in order to be 824 compatible with MGI sequencers using the MGIEasy Universal Library Conversion Kit. The kit circularizes 825 the libraries making them compatible for MGI systems. To sequence the circularized libraries, they were 826 first amplified by rolling circle amplification, resulting in a long DNA strand which individually folds into a 827 tight ball (i.e. a DNA nanoball) where one library fragment results in one DNA nanoball. Before loading 828 into the flowcells, the amplified nanoballs were quantified with a Qubit ssDNA HS Assay kit 829 (ThermoFisher), normalized and loaded onto the sequencing flowcell using the auto-loader method 830 (auto-loader MGI-DL-200R). The flowcells have a functionalized surface that captures and immobilizes 831 the nanoballs in a grid pattern. Typically, two libraries were loaded per lane for the single cell RNA 832 libraries. The DNBSEQ-G400RS PE100 MGI kit with App-A primers was used for single cell RNA library 833 sequencing. The DNBSEQ-G400RS PE150 MGI kit with App-A primers was used for single cell DNA library 834 sequencing.
- The flowcells were sequenced on a DNBSEQ-G400 MGI sequencer. Single cell RNA libraries were sequenced as follows: 28 cycles for read1, 150 cycles for read2 and 8 cycles for the i7 index. Single cell DNA libraries were sequenced as follows: 151 cycles for Read1, 151 cycles for Read2 and 8 cycles for the i5 index. Because libraries must be color-balanced for all cycles sequenced in order to maintain a minimum ratio of 0.125 for each base at each cycle, color-balanced single index adapters (10x Genomics) were used for libraries sequenced on MGI.
- A subset of 23 libraries were sequenced on the Illumina NovaSeq 6000 platform using S4 flowcells. To ensure uniform loading of the libraries, a preliminary pool was sequenced on Illumina iSeq and the
- 20

843 library proportions were readjusted accordingly. Another subset of 12 libraries were sequenced on the
844 Illumina HiSeq 4000 system typically with one library per lane.

845 Although the MGI sequencer has onboard capability to demultiplex samples, we chose to use 846 independent tools to demultiplex the raw fastq files for each lane to give us the flexibility to reprocess if 847 needed. The fastq files generated using the balanced single index adapters were merged for each library 848 after demultiplexing. The MGI runs demultiplexed were mainly by fastg-multx 849 (https://github.com/brwnj/fastq-multx) but also using fgbio/DemuxFastqs 850 (http://fulcrumgenomics.github.io/fgbio/tools/latest/DemuxFastqs.html). In both instances we used a 851 mismatch of 1. Illumina runs were demultiplexed using the the standard bcl2fastq tool.

853 scRNA-seq Data Processing and Analysis

854 **Read processing and alignment**

After polyA-trimming via cutadapt $(v3.2)^{86}$, reads were pseudo-aligned to the GRCh38 reference transcriptome (ENSEMBL release 96) with kallisto $(v0.46.2)^{87}$ using the default kmer size of 31. The pseudo-aligned reads were processed into a cell-by-gene count matrix using bustools $(0.40.0)^{88}$. Cell barcodes were filtered using the whitelist (v3) provided by 10xGenomics. All further processing was done in scanpy $(v.1.7.1)^{89}$.

861

862 Quality control and normalization

Quality control was performed for each sample independently as follows. Cell barcodes with less than 1000 counts or less than 500 genes expressed or with more than 10% mitochondrial gene expression were removed. Doublet cells were identified using scrublet⁹⁰, and any cell barcode with a scrublet score > 0.2 was removed. Only coding genes were retained in the final count matrix. Expression profiles were normalized by total counts, the 4000 most highly variable genes being identified⁹¹, renormalized, logtransformed and z-scored. The data were projected onto the first 50 principal components.

After the above per-sample preprocessing, samples were pooled and integrated using Harmony²⁰ on the first 50 principal components with a maximum of 25 iterations. A nearest neighbor graph (k=15) was calculated on the Harmony-corrected principal components space. Datasets were visualized in 2D via UMAP⁹² and initialized with PAGA⁹³ coordinates. The nearest neighbor graph was clustered with the Leiden algorithm⁹⁴. The processed datasets were visualized interactively using Cellbrowser⁹⁵ allowing for easy access and exploration across teams and laboratories.

875

876 Cell type calling

877 Cell types were called using the Human Cell Landscape (HCL) reference dataset²¹. Briefly, the raw 878 expression profile x_i of cells i was normalized by total counts and log-transformed $y_{ij} = \log(1 + x_{ij} / \sum x_{ij})$

879 j with x_{ij} the counts of genes j in each cell i. Cells were compared to the 880 Human Cell Landscape reference by Pearson correlation, and the reference profile with the highest 881 correlation determined the cell type call. If the highest correlation was below 0.3, the cell type was 882 defined as "unknown".

The per-cell types were categorized on a per-cluster level based priors calls with the expression of markers indicated from a range of sources including Cell Ontology⁹⁶ and reference materials from Thermofisher, Abcam and BioLegend.

887

888 Fine-grained labels were produced using a number of techniques. To fine grain the squamous 889 esophageal epithelium we compared our esophageal dataset to 6 esophageal samples from the Human 890 Cell Atlas⁹⁷, HCA-derived gene signatures were produced from the top 50 most differentially expressed 891 genes for each cell type from the HCA data. Using the single-cell gene set scoring method GSSNNG, we 892 scored the cell type labels using those HCA-derived signatures. The squamous epithelium subtypes 893 (upper, intermediate, basal) were clearly indicated through high gene set scores in the CRUK dataset. 894 Also, the HCA signatures clearly identified our cell types including fibroblasts and glandular gastro-895 intestinal (GI) epithelium. Some HCA signatures were non-specific in our dataset including the 896 esophageal basal cell layer, the venous endothelium, and the ductal epithelium. Otherwise, fine graining 897 was performed by using well known marker genes from the literature.

898

899 Sample PCA and clustering

900 In order to apply PCA, sample level clustering, and perform differential expression (as described below), 901 pseudo-bulk profiles were produced for each coarse-grained cell label and over all cells. To produce a 902 pseudo-bulk profile computationally, cells of a given type were selected and raw gene expression counts 903 were summed. For a given cell type, such as for example CD8 T cells, this produced one gene expression 904 profile per sample. PCA was performed using R 'prcomp', principal components (eigenvectors) were 905 recovered and used for plotting of principal components. Clustering of samples was performed using the 906 R hclust function with average linkage.

907

908 Differential expression

909 In order to estimate differential expression between the tissue diagnosis on a per cell basis, we applied 910 DESeq2 to pseudo-bulk profiles while accounting for sequencing depth and patient heterogeneity using 911 the model gene ~ patient + cell_counts + avg_molecules + dx where the patient is patient ID (each 912 patient has several different samples), cell_counts is the number of cells observed in a given sample, 913 avg_molecules is the mean of gene counts, dx is the tissue diagnosis. The goal is to find genes where the 914 variations in expression patterns are explained more by the change in tissue diagnosis rather than from 915 other considered factors.

916

917 There was considerable bias introduced from ambient RNA which produced false positive results⁹⁸. In 918 order to identify differentially expressed genes that were artifacts the following heuristic was used: If a 919 gene was found to be differentially expressed in a cell type and was also differentially expressed in other 920 cell types, and the ambient profile was correlated with the pseudo-bulk profile (across samples) and 921 statistically associated with the tissue diagnosis [other metrics], then the DEG was removed from the 922 results. Gene expression heatmaps were created by taking the collection of differentially expressed 923 genes, and scoring genes based on association with disease progression. In particular, for the purpose of 924 visualization, genes were selected through association with (mNE, mNS, M) vs. (D,T) using logistic 925 regression. 926

927 Gene set scoring

928 For each coarse-grained cell type, differentially expressed genes with a max log2 fold change (between

- 929 tissue diagnoses) of at least 0.58 and adjusted p-value of 0.05 were submitted to the Enrichr service²⁶.
- 930 Pathway enrichment tables were downloaded for BioPlanet 2019, MSigDB Hallmarks, KEGG 2021, and
- 931 WikiPathways 2021. (see Suppl. Table S2)
- 932

933 Statistical analysis of cell type proportion changes

934 Changes in cell type proportions across diagnoses were analyzed with scCODA⁹⁹. Changes were 935 computed relative to mNE samples and reference cell types were selected based on the cell type with 936 the least dispersion across diagnosis. To account for inter-patient differences, and systematic differences 937 in cell type composition between biopsy/resection samples, those were included as covariates into the 938 scCODA model. Model inference was performed using HMC and 60000 iterations. MCMC chains were 939 inspected manually for convergence. Statistically significant covariates were determined using the 940 model's posterior inclusion probabilities and an FDR of 0.05.

941

942 Copy Number Variation inference from scRNAseq

We used a python re-implementation¹⁰⁰ of the inferCNV algorithm ⁴⁸ to call copy number variation (CNV) 943 944 in the single cell data. First, all samples across all diagnoses were pooled and epithelial cells were 945 extracted based on cell type calling. Any epithelial cell from a mNE/mNS sample was assigned to the 946 reference set of inferCNV, any other epithelial cell was assigned to the query set in inferCNV. After 947 filtering out lowly expressed genes (mean expression <0.1) and standard inferCNV preprocessing, the 948 data were smoothed along chromosomal coordinates with a window size of 101 and a step size of 2. The 949 CNV burden s is of a single cell s was estimated as s i = $\sum i |X_{ij}|$, where s X_{ij} is the 950 inferred gain/loss in cell \$i\$, gene window \$j\$. The 99% quantile of the CNV burden \$s_i\$ in mNE/mNS 951 epithelial cells was calculated and, assuming no CNV's present in mNE/mNS samples, any non-reference 952 cells exceeding this threshold were classified as containing CNVs.

953

954 Proteomics Methods

955 Chemicals

LC-MS-grade acetonitrile (ACN) and water were obtained from Burdick & Jackson (Muskegon, MI).
Reagents for protein chemistry, including sodium dodecyl sulfate (SDS), ammonium bicarbonate,
iodoacetamide (IAA), dithiothreitol (DTT), sequencing-grade endoproteinase Lys-C, and formic acid (FA)
were purchased from Sigma-Aldrich (St. Louis, MO). Sequencing-grade trypsin was purchased from
Promega (Madison, WI). Glycerol-free PNGase F was purchased from New England BioLabs (Ipswich,
MA).

962

963 Sample Preparation

Proteomic analysis was performed as described in Bons *et al.*¹⁰¹. Briefly, fresh esophageal tissues were minced in small pieces, weighed, and flash frozen for storage at -80°C. The ECM fraction was isolated from the frozen tissues using the Compartment Protein Extraction Kit (Millipore, #2145) as per manufacturer's protocol. About 1/10 of purified ECM was used to assess ECM protein enrichment purity and yield by Western blot analysis. From the remaining purified ECM fraction, proteins were solubilized by agitation for 10 minutes in a solution containing 1% SDS, 50 mM DTT and 1X NuPAGE lithium dodecyl 970 sulfate (LDS) sample buffer (Life Technologies, Carlsbad, CA), followed by sonication for 10 minutes, and 971 finally heating at 85 °C for 1 hour with agitation. Solubilized proteins were concentrated in a single 972 stacking acrylamide Bis-Tris gel, in-gel reduced with 10 mM DTT, and alkylated with 55 mM IAA. Finally, 973 proteins were in-gel digested with 250 ng of sequencing-grade endoproteinase Lys-C in 25 mM 974 ammonium bicarbonate at 37 °C for 2 hours with agitation, followed by an overnight incubation with 975 250 ng sequencing-grade trypsin in 25 mM ammonium bicarbonate at 37 °C with agitation. After tryptic 976 peptide extraction, samples were vacuum dried, resuspended in 25 mM ammonium bicarbonate, and 977 peptides were deglycosylated with 3 μ L (1,500 U) of glycerol-free PNGase F at 37 °C for 3 hours with 978 agitation. The reaction was quenched by adding FA to a final concentration of 1%. Peptide samples were 979 finally desalted using stage-tips made in-house containing a C₁₈ disk, vacuum dried, and re-suspended in 980 aqueous 0.2% FA spiked with indexed retention time peptide standards (iRT, Biognosys, Schlieren, 981 Switzerland)¹⁰².

982 LC-DIA-MS Analysis

983 LC-MS/MS were performed on an Eksigent Ultra Plus nano-LC 2D HPLC system (Dublin, CA) combined 984 with a cHiPLC system directly connected to an orthogonal quadrupole time-of-flight (Q-TOF) SCIEX 985 TripleTOF 6600 mass spectrometer (SCIEX, Redwood City, CA). The solvent system consisted of 2% ACN, 986 0.1% FA in H₂O (solvent A) and 98% ACN, 0.1% FA in H₂O (solvent B). Proteolytic peptides were loaded 987 onto a C₁₈ pre-column chip (200 μ m × 6 mm ChromXP C18-CL chip, 3 μ m, 300 Å; SCIEX) and washed at 2 988 μ L/minute for 10 minutes with the loading solvent (0.1% FA in H₂O) for desalting. Peptides were transferred to the 75 µm × 15 cm ChromXP C18-CL chip, 3 µm, 300 Å (SCIEX) and eluted at 300 nL/min 989 990 with the following gradient of solvent B: 5% for 5 min, linear from 5% to 8% in 15 min, linear from 8% to 991 35% in 97 min, and up to 80% in 20 min, with a total gradient length of 180 min. Samples were analyzed 992 by data-independent acquisition (DIA) using 64 variable-sized windows covering the m/z 400-1,250 range (Suppl. Table S7)^{103–105}. MS scans were collected with 250-ms accumulation time, and MS/MS 993 994 scans with 45-ms accumulation time in "high-sensitivity" mode. The collision energy (CE) for each 995 segment was based on the z=2+ precursor ion centered within the window with a CE spread of 10 or 15 996 eV.

997 MS DIA Data Processing

998 DIA data were processed in Spectronaut (version 14.10.201222.47784) (Biognosys) using a pan-human 999 library containing 10,316 proteins¹⁰⁶. Data extraction parameters were selected as dynamic using non-1000 linear iRT calibration. Identification was performed using 1% precursor and protein q-values. 1001 Quantification was based on the MS/MS peak areas of the 3-6 best fragment ions per precursor ion, 1002 local normalization was applied, and iRT profiling was selected. Differential protein abundance analysis 1003 was performed using paired t-tests, and p-values were corrected for multiple testing using the Storey 1004 method¹⁰⁷. Protein groups with at least two unique peptides, q-value \leq 0.001, and absolute Log2(fold-1005 change) \geq 0.58 were considered to be significantly altered (Suppl. Table S6).

1006

1007 Atomic Force Microscopy Methods

1008 Snap frozen patient samples were cryosectioned. A reference slide has been H&E stained from the 1009 adjacent test sample to visualize the location of epithelium and stroma. Unfixed slides were tested with 1010 AFM for stiffness and distribution of measurements were visualized using AFM manufacturer's software

- 1011 (Fig. S8).
- 1012

1013 CODEX Multiplexed Protein Imaging Methods

1014 CODEX Array Creation and Pathology Annotation

Imaging data were collected from 5 human donors, each of whom constituting a dataset. Each dataset 1015 1016 included tissue sections taken from individually diagnosed formalin fixed paraffin embedded (FFPE) 1017 tissue blocks that were combined onto the same coverslip (cut at 4 μ m thickness). To ensure accurate 1018 disease phase diagnosis, three pathologists independently evaluated the H&E staining of the sections 1019 performed on the same tissue sections as used for the CODEX multiplexed imaging (Fig. S9B-C). They 1020 called disease phase granular diagnosis (e.g., mNE, mNS, M), and estimated percentages of type of 1021 epithelium in each image (e.g., % squamous, % metaplasia, % dysplasia, % tumor). The pathologists 1022 scores were then aggregated and averaged (Suppl. Table S8).

1023

1024 CODEX Antibody Conjugation and Panel Creation

1025 CODEX multiplexed protein imaging was executed according to the CODEX staining and imaging protocol 1026 previously described⁶³. Antibody panels were chosen to include targets that identify subtypes of 1027 intestinal epithelium and stromal cells, and cells of the innate and adaptive immune system. Detailed 1028 panel information can be found in Suppl. Table S9. Each antibody was conjugated to a unique 1029 oligonucleotide barcode, after which the tissues were stained with the antibody-oligonucleotide 1030 conjugates and validated to ensure that staining patterns matched expected patterns already 1031 established for IHC within positive control tissues of the esophagus or tonsil. Similarly, Hematoxylin and 1032 Eosin morphology stainings were used to confirm location of marker staining. First, antibody-1033 oligonucleotide conjugates were tested in low-plex fluorescence assays and signal-to-noise ratio was 1034 also evaluated at this step, then conjugates were tested all together in a single CODEX multicycle.

1035

1036 CODEX Multiplexed Protein Imaging

1037 The tissue arrays were then stained with the complete validated panel of CODEX antibodies and 1038 imaged⁶³. Briefly, the workflow entailed cyclic stripping, annealing, and imaging of fluorescently labeled 1039 oligonucleotides complementary to the oligonucleotide on the conjugate. After validation of the 1040 antibody-oligonucleotide conjugate panel, a test CODEX multiplexed assay was run, during which signal-1041 to-noise ratio was again evaluated, and the optimal dilution, exposure time, and appropriate imaging 1042 cycle was evaluated for each conjugate (Suppl. Table S9). Finally, each coverslip array underwent CODEX 1043 multiplexed imaging.

1044

1045 CODEX Data Processing

1046 Raw imaging data were then processed using the CODEX Uploader for image stitching, drift 1047 compensation, deconvolution, and cycle concatenation. Processed data were then segmented using the 1048 CellVisionSegmenter, a neural network R-CNN-based single-cell segmentation algorithm 1049 (<u>https://github.com/michaellee1/CellSeg</u>)¹⁰⁸. After upload, the images were again evaluated for specific 1050 signal: any marker that produced an untenable pattern or a low signal-to-noise ratio was excluded from 1051 the ensuing analysis. Uploaded images were visualized in ImageJ (https://imagej.nih.gov/ij/).

1053 CODEX Cell Type Analysis

1054 Cell type identification was done following the methods developed previously⁶⁷. Briefly, nucleated cells
1055 were selected by gating DRAQ5, Hoechst double-positive cells, followed by z-normalization of protein
1056 markers used for clustering (some phenotypic markers were not used in the unsupervised clustering).
1057 The data were overclustered with X-shift (https://github.com/nolanlab/vortex). Clusters were assigned a
1058 cell type based on average cluster protein expression and location within the image. Impure clusters
1059 were split or reclustered following mapping back to the original fluorescent images.

1060

1061 CODEX Cell-cell colocalization analysis and Shannon's Index

To evaluate enriched cell-cell interactions, we calculated the frequency of neighbors using a nearest neighbor (n=10 neighbors) approach and compared the frequency of occurrences to 10,000 permutations of the cell type locations. We filtered this list for cell-cell interactions enriched within certain conditions compared to the other disease states. Shannon's Diversity Index was calculated by taking the negative sum of each proportion multiplied by the natural logarithm of the proportion.

1067

1068 **CODEX Neighborhood and Community Identification Analysis**

- Neighborhood analysis was performed as described previously^{109,110}. Briefly, this analysis involved (i) 1069 1070 taking windows of cells across the entire cell type map of a tissue with each cell as the center of a 1071 window, (ii) calculating the number of each cell type within this window, (iii) clustering these vectors, 1072 and (iv) assigning overall structure based on the average composition of the cluster. Neighborhoods 1073 were overclustered to 30 clusters. These clusters were mapped back to the tissue and evaluated for cell 1074 type enrichments to determine overall structure and merged down into the final unique neighborhoods. 1075 Communities were determined similar to how multicellular neighborhoods were determined with some 1076 minor differences ⁶⁵. Briefly, the cells in the neighborhood tissue maps were taken with a larger window 1077 size of 100 nearest neighbors. These windows were then taken across the entirety of the tissue and the 1078 vectors clustered with k-means clustering and overclustering with 20 total clusters. These clusters were 1079 mapped back to the tissue and evaluated for neighborhood composition and enrichment to determine
- 1080 overall community type.

1081 DECLARATION OF INTERESTS

- 1082 G.P.N. has equity in and is a scientific advisory board member of Akoya Biosciences, Inc.
- 1083 C.M.S. is a scientific advisor to, has stock options in, and has received research funding from
- 1084 Enable Medicine Inc., and is a scientific advisor to AstraZeneca plc.
- 1085 The other authors declare no competing interests.

1086 FUNDING

1087 This work was supported by a Cancer Research UK Grand Challenge (CRUK grant 29068). Additional 1088 support from the Tlsty Lab at UCSF (TDT: CRUK grant 27145, National Cancer Institute Award

1089 5R35CA197694, PG: National Cancer Institute Award 5R50CA211543), McGill University Thoracic and

1090 Upper GI Cancer Research Laboratories (LLF: CRUK grant 29071), the Advanced Genomic Technologies

1091 Laboratory (IR: CRUK grant 29078), and the Huang lab (SH: National Institute of General Medical

1092 Sciences Award 5R01GM135396) is greatly appreciated.

1093 **REFERENCES**

- 1. Uhlenhopp, D.J., Then, E.O., Sunkara, T., and Gaduputi, V. (2020). Epidemiology of esophageal cancer: update in global trends, etiology and risk factors. Clin. J. Gastroenterol. *13*, 1010–1021. 10.1007/s12328-020-01237-x.
- Smyth, E.C., Lagergren, J., Fitzgerald, R.C., Lordick, F., Shah, M.A., Lagergren, P., and Cunningham, D. (2017). Oesophageal cancer. Nat. Rev. Dis. Primer *3*, 17048. 10.1038/nrdp.2017.48.
- 3. Yang, J., Liu, X., Cao, S., Dong, X., Rao, S., and Cai, K. (2020). Understanding Esophageal Cancer: The Challenges and Opportunities for the Next Decade. Front. Oncol. *10*, 1727. 10.3389/fonc.2020.01727.
- 4. McColl, K.E.L. (2019). What is causing the rising incidence of esophageal adenocarcinoma in the West and will it also happen in the East? J. Gastroenterol. *54*, 669–673. 10.1007/s00535-019-01593-7.
- 5. Hur, C., Miller, M., Kong, C.Y., Dowling, E.C., Nattinger, K.J., Dunn, M., and Feuer, E.J. (2013). Trends in Esophageal Adenocarcinoma Incidence and Mortality. Cancer *119*, 1149–1158. 10.1002/cncr.27834.
- Cancer Genome Atlas Research Network, Analysis Working Group: Asan University, BC Cancer Agency, Brigham and Women's Hospital, Broad Institute, Brown University, Case Western Reserve University, Dana-Farber Cancer Institute, Duke University, Greater Poland Cancer Centre, et al. (2017). Integrated genomic characterization of oesophageal carcinoma. Nature *541*, 169–175. 10.1038/nature20805.
- Nowicki-Osuch, K., Zhuang, L., Jammula, S., Bleaney, C.W., Mahbubani, K.T., Devonshire, G., Katz-Summercorn, A., Eling, N., Wilbrey-Clark, A., Madissoon, E., et al. (2021). Molecular phenotyping reveals the identity of Barrett's esophagus and its malignant transition. Science *373*, 760–767. 10.1126/science.abd1449.
- 8. Krishnamoorthi, R., Mohan, B.P., Jayaraj, M., Wang, K.K., Katzka, D.A., Ross, A., Adler, D.G., and Iyer, P.G. (2020). Risk of progression in Barrett's esophagus indefinite for dysplasia: a systematic review and meta-analysis. Gastrointest. Endosc. *91*, 3-10.e3. 10.1016/j.gie.2019.07.037.
- 9. Weaver, J.M.J., Ross-Innes, C.S., Shannon, N., Lynch, A.G., Forshew, T., Barbera, M., Murtaza, M., Ong, C.-A.J., Lao-Sirieix, P., Dunning, M.J., et al. (2014). Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nat. Genet. *46*, 837–843. 10.1038/ng.3013.
- Killcoyne, S., Gregson, E., Wedge, D.C., Woodcock, D.J., Eldridge, M.D., de la Rue, R., Miremadi, A., Abbas, S., Blasko, A., Kosmidou, C., et al. (2020). Genomic copy number predicts esophageal cancer years before transformation. Nat. Med. 26, 1726–1732. 10.1038/s41591-020-1033-y.
- 11. Katz-Summercorn, A.C., Jammula, S., Frangou, A., Peneva, I., O'Donovan, M., Tripathi, M., Malhotra, S., di Pietro, M., Abbas, S., Devonshire, G., et al. (2022). Multi-omic cross-

sectional cohort study of pre-malignant Barrett's esophagus reveals early structural variation and retrotransposon activity. Nat. Commun. *13*, 1407. 10.1038/s41467-022-28237-4.

- Stachler, M.D., Camarda, N.D., Deitrick, C., Kim, A., Agoston, A.T., Odze, R.D., Hornick, J.L., Nag, A., Thorner, A.R., Ducar, M., et al. (2018). Detection of Mutations in Barrett's Esophagus Before Progression to High-Grade Dysplasia or Adenocarcinoma. Gastroenterology *155*, 156–167. 10.1053/j.gastro.2018.03.047.
- 13. Luebeck, J., Ng, A.W.T., Galipeau, P.C., Li, X., Sanchez, C.A., Katz-Summercorn, A.C., Kim, H., Jammula, S., He, Y., Lippman, S.M., et al. (2023). Extrachromosomal DNA in the cancerous transformation of Barrett's oesophagus. Nature. 10.1038/s41586-023-05937-5.
- Maag, J.L.V., Fisher, O.M., Levert-Mignon, A., Kaczorowski, D.C., Thomas, M.L., Hussey, D.J., Watson, D.I., Wettstein, A., Bobryshev, Y.V., Edwards, M., et al. (2017). Novel Aberrations Uncovered in Barrett's Esophagus and Esophageal Adenocarcinoma Using Whole Transcriptome Sequencing. Mol. Cancer Res. MCR *15*, 1558–1569. 10.1158/1541-7786.MCR-17-0332.
- Nowicki-Osuch, K., Zhuang, L., Cheung, T.S., Black, E.L., Masque-Soler, N., Devonshire, G., Redmond, A.M., Freeman, A., di Pietro, M., Pilonis, N., et al. (2023). Single-cell RNA sequencing unifies developmental programs of Esophageal and Gastric Intestinal Metaplasia. Cancer Discov., CD-22-0824. 10.1158/2159-8290.CD-22-0824.
- 16. Murphy, K.J., Chambers, C.R., Herrmann, D., Timpson, P., and Pereira, B.A. (2021). Dynamic Stromal Alterations Influence Tumor-Stroma Crosstalk to Promote Pancreatic Cancer and Treatment Resistance. Cancers *13*, 3481. 10.3390/cancers13143481.
- Mishra, R., Haldar, S., Placencio, V., Madhav, A., Rohena-Rivera, K., Agarwal, P., Duong, F., Angara, B., Tripathi, M., Liu, Z., et al. Stromal epigenetic alterations drive metabolic and neuroendocrine prostate cancer reprogramming. J. Clin. Invest. *128*, 4472–4484. 10.1172/JCI99397.
- 18. Xu, M., Zhang, T., Xia, R., Wei, Y., and Wei, X. (2022). Targeting the tumor stroma for cancer therapy. Mol. Cancer *21*, 208. 10.1186/s12943-022-01670-1.
- 19. Greten, F.R., and Grivennikov, S.I. (2019). Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity *51*, 27–41. 10.1016/j.immuni.2019.06.025.
- Korsunsky, I., Millard, N., Fan, J., Slowikowski, K., Zhang, F., Wei, K., Baglaenko, Y., Brenner, M., Loh, P.-R., and Raychaudhuri, S. (2019). Fast, sensitive and accurate integration of single-cell data with Harmony. Nat. Methods *16*, 1289–1296. 10.1038/s41592-019-0619-0.
- Han, X., Zhou, Z., Fei, L., Sun, H., Wang, R., Chen, Y., Chen, H., Wang, J., Tang, H., Ge, W., et al. (2020). Construction of a human cell landscape at single-cell level. Nature *581*, 303–309. 10.1038/s41586-020-2157-4.
- 22. Parikh, K., Antanaviciute, A., Fawkner-Corbett, D., Jagielowicz, M., Aulicino, A., Lagerholm, C., Davis, S., Kinchen, J., Chen, H.H., Alham, N.K., et al. (2019). Colonic epithelial cell diversity in health and inflammatory bowel disease. Nature *567*, 49–55. 10.1038/s41586-019-0992-y.

- 23. Gutierrez-Gonzalez, L., Graham, T.A., Rodriguez-Justo, M., Leedham, S.J., Novelli, M.R., Gay, L.J., Ventayol-Garcia, T., Green, A., Mitchell, I., Stoker, D.L., et al. (2011). The clonal origins of dysplasia from intestinal metaplasia in the human stomach. Gastroenterology *140*, 1251-1260.e1-6. 10.1053/j.gastro.2010.12.051.
- 24. Squair, J.W., Gautier, M., Kathe, C., Anderson, M.A., James, N.D., Hutson, T.H., Hudelle, R., Qaiser, T., Matson, K.J.E., Barraud, Q., et al. (2021). Confronting false discoveries in single-cell differential expression. Nat. Commun. *12*, 5692. 10.1038/s41467-021-25960-2.
- 25. Love, M.I., Huber, W., and Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. *15*, 550. 10.1186/s13059-014-0550-8.
- 26. Xie, Z., Bailey, A., Kuleshov, M.V., Clarke, D.J.B., Evangelista, J.E., Jenkins, S.L., Lachmann, A., Wojciechowicz, M.L., Kropiwnicki, E., Jagodnik, K.M., et al. (2021). Gene Set Knowledge Discovery with Enrichr. Curr. Protoc. *1*, e90. 10.1002/cpz1.90.
- 27. Chen, E.Y., Tan, C.M., Kou, Y., Duan, Q., Wang, Z., Meirelles, G.V., Clark, N.R., and Ma'ayan, A. (2013). Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics *14*, 128. 10.1186/1471-2105-14-128.
- McDonald, S.A.C., Lavery, D., Wright, N.A., and Jansen, M. (2015). Barrett oesophagus: lessons on its origins from the lesion itself. Nat. Rev. Gastroenterol. Hepatol. *12*, 50–60. 10.1038/nrgastro.2014.181.
- 29. Barbera, M., and Fitzgerald, R.C. (2010). Cellular origin of Barrett's metaplasia and oesophageal stem cells. Biochem. Soc. Trans. *38*, 370–373. 10.1042/BST0380370.
- 30. Jiang, M., Li, H., Zhang, Y., Yang, Y., Lu, R., Liu, K., Lin, S., Lan, X., Wang, H., Wu, H., et al. (2017). Transitional basal cells at the squamous–columnar junction generate Barrett's oesophagus. Nature *550*, 529–533. 10.1038/nature24269.
- 31. Hanahan, D. (2022). Hallmarks of Cancer: New Dimensions. Cancer Discov. *12*, 31–46. 10.1158/2159-8290.CD-21-1059.
- 32. Buechler, M.B., Pradhan, R.N., Krishnamurty, A.T., Cox, C., Calviello, A.K., Wang, A.W., Yang, Y.A., Tam, L., Caothien, R., Roose-Girma, M., et al. (2021). Cross-tissue organization of the fibroblast lineage. Nature *593*, 575–579. 10.1038/s41586-021-03549-5.
- 33. Lendahl, U., Muhl, L., and Betsholtz, C. (2022). Identification, discrimination and heterogeneity of fibroblasts. Nat. Commun. *13*, 3409. 10.1038/s41467-022-30633-9.
- Lee, S.-H., Contreras Panta, E.W., Gibbs, D., Won, Y., Min, J., Zhang, C., Roland, J.T., Hong, S.-H., Sohn, Y., Krystofiak, E., et al. (2023). Apposition of fibroblasts with metaplastic gastric cells promotes dysplastic transition. Gastroenterology, S001650852300731X. 10.1053/j.gastro.2023.04.038.
- 35. De Palma, M., Biziato, D., and Petrova, T.V. (2017). Microenvironmental regulation of tumour angiogenesis. Nat. Rev. Cancer *17*, 457–474. 10.1038/nrc.2017.51.
- 36. Raza, A., Franklin, M.J., and Dudek, A.Z. (2010). Pericytes and vessel maturation during tumor angiogenesis and metastasis. Am. J. Hematol. *85*, 593–598. 10.1002/ajh.21745.

- Dias, D.O., Kalkitsas, J., Kelahmetoglu, Y., Estrada, C.P., Tatarishvili, J., Holl, D., Jansson, L., Banitalebi, S., Amiry-Moghaddam, M., Ernst, A., et al. (2021). Pericyte-derived fibrotic scarring is conserved across diverse central nervous system lesions. Nat. Commun. *12*, 5501. 10.1038/s41467-021-25585-5.
- 38. He, S., Wang, L.-H., Liu, Y., Li, Y.-Q., Chen, H.-T., Xu, J.-H., Peng, W., Lin, G.-W., Wei, P.-P., Li, B., et al. (2020). Single-cell transcriptome profiling of an adult human cell atlas of 15 major organs. Genome Biol. *21*, 294. 10.1186/s13059-020-02210-0.
- 39. Bosma, E.K., van Noorden, C.J.F., Schlingemann, R.O., and Klaassen, I. (2018). The role of plasmalemma vesicle-associated protein in pathological breakdown of blood-brain and blood-retinal barriers: potential novel therapeutic target for cerebral edema and diabetic macular edema. Fluids Barriers CNS *15*, 24. 10.1186/s12987-018-0109-2.
- Schupp, J.C., Adams, T.S., Cosme, C., Raredon, M.S.B., Yuan, Y., Omote, N., Poli, S., Chioccioli, M., Rose, K.-A., Manning, E.P., et al. (2021). Integrated Single-Cell Atlas of Endothelial Cells of the Human Lung. Circulation *144*, 286–302. 10.1161/CIRCULATIONAHA.120.052318.
- 41. Lee, H.-W., Xu, Y., He, L., Choi, W., Gonzalez, D., Jin, S.-W., and Simons, M. (2021). Role of Venous Endothelial Cells in Developmental and Pathologic Angiogenesis. Circulation *144*, 1308–1322. 10.1161/CIRCULATIONAHA.121.054071.
- 42. Leu, A.J., Berk, D.A., Lymboussaki, A., Alitalo, K., and Jain, R.K. (2000). Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res. *60*, 4324–4327.
- 43. Padera, T.P., Kadambi, A., di Tomaso, E., Carreira, C.M., Brown, E.B., Boucher, Y., Choi, N.C., Mathisen, D., Wain, J., Mark, E.J., et al. (2002). Lymphatic metastasis in the absence of functional intratumor lymphatics. Science *296*, 1883–1886. 10.1126/science.1071420.
- 44. Crome, S.Q., Nguyen, L.T., Lopez-Verges, S., Yang, S.Y.C., Martin, B., Yam, J.Y., Johnson, D.J., Nie, J., Pniak, M., Yen, P.H., et al. (2017). A distinct innate lymphoid cell population regulates tumor-associated T cells. Nat. Med. *23*, 368–375. 10.1038/nm.4278.
- 45. Corvino, D., Kumar, A., and Bald, T. (2022). Plasticity of NK cells in Cancer. Front. Immunol. *13*, 888313. 10.3389/fimmu.2022.888313.
- Fristedt, R., Borg, D., Hedner, C., Berntsson, J., Nodin, B., Eberhard, J., Micke, P., and Jirström, K. (2016). Prognostic impact of tumour-associated B cells and plasma cells in oesophageal and gastric adenocarcinoma. J. Gastrointest. Oncol. 7, 848–859. 10.21037/jgo.2016.11.07.
- Li, X., Paulson, T.G., Galipeau, P.C., Sanchez, C.A., Liu, K., Kuhner, M.K., Maley, C.C., Self, S.G., Vaughan, T.L., Reid, B.J., et al. (2015). Assessment of Esophageal Adenocarcinoma Risk Using Somatic Chromosome Alterations in Longitudinal Samples in Barrett's Esophagus. Cancer Prev. Res. Phila. Pa *8*, 845–856. 10.1158/1940-6207.CAPR-15-0130.
- 48. Tickle T, Tirosh I, Georgescu C, Brown M, Haas B (2019). inferCNV of the Trinity CTAT Project.

- Paulson, T.G., Maley, C.C., Li, X., Li, H., Sanchez, C.A., Chao, D.L., Odze, R.D., Vaughan, T.L., Blount, P.L., and Reid, B.J. (2009). Chromosomal instability and copy number alterations in Barrett's esophagus and esophageal adenocarcinoma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. *15*, 3305–3314. 10.1158/1078-0432.CCR-08-2494.
- 50. Stachler, M.D., Taylor-Weiner, A., Peng, S., McKenna, A., Agoston, A.T., Odze, R.D., Davison, J.M., Nason, K.S., Loda, M., Leshchiner, I., et al. (2015). Paired exome analysis of Barrett's esophagus and adenocarcinoma. Nat. Genet. *47*, 1047–1055. 10.1038/ng.3343.
- Shimshoni, E., Merry, G.E., Milot, Z.D., Oh, C.Y., Horvath, V., Gould, R.A., Caruso, J.A., Chen-Tanyolac, C., Gascard, P., Sangwan, V., et al. (2023). Epithelial-Stromal Interactions in Barrett's Esophagus Modeled in Human Organ Chips. Gastro Hep Adv., S2772572323000444. 10.1016/j.gastha.2023.03.009.
- 52. Norreen-Thorsen, M., Struck, E.C., Öling, S., Zwahlen, M., Von Feilitzen, K., Odeberg, J., Lindskog, C., Pontén, F., Uhlén, M., Dusart, P.J., et al. (2022). A human adipose tissue cell-type transcriptome atlas. Cell Rep. *40*, 111046. 10.1016/j.celrep.2022.111046.
- 53. Wynn, T.A. (2008). Cellular and molecular mechanisms of fibrosis. J. Pathol. *214*, 199–210. 10.1002/path.2277.
- 54. Wells, R.G. (2008). Cellular sources of extracellular matrix in hepatic fibrosis. Clin. Liver Dis. *12*, 759–768, viii. 10.1016/j.cld.2008.07.008.
- 55. Saadi, A., Das, M., Clemons, N., Zhang, C., Ferguson, M., Tokiwa, G., Serikawa, K., Hardwick, J., Dai, H., Carlini, L., et al. (2014). A potential role for Periostin in Barrett's carcinogenesis. Cancer Epidemiol. Biomarkers Prev. *16*, B28.
- 56. Onieva, J.L., Xiao, Q., Berciano-Guerrero, M.-Á., Laborda-Illanes, A., de Andrea, C., Chaves, P., Piñeiro, P., Garrido-Aranda, A., Gallego, E., Sojo, B., et al. (2022). High IGKC-Expressing Intratumoral Plasma Cells Predict Response to Immune Checkpoint Blockade. Int. J. Mol. Sci. *23*, 9124. 10.3390/ijms23169124.
- 57. Schmidt, M., Micke, P., Gehrmann, M., and Hengstler, J.G. (2012). Immunoglobulin kappa chain as an immunologic biomarker of prognosis and chemotherapy response in solid tumors. Oncoimmunology *1*, 1156–1158. 10.4161/onci.21653.
- 58. Fiore, V.F., Krajnc, M., Quiroz, F.G., Levorse, J., Pasolli, H.A., Shvartsman, S.Y., and Fuchs, E. (2020). Mechanics of a multilayer epithelium instruct tumour architecture and function. Nature *585*, 433–439. 10.1038/s41586-020-2695-9.
- 59. Cross, S.E., Jin, Y.-S., Rao, J., and Gimzewski, J.K. (2007). Nanomechanical analysis of cells from cancer patients. Nat. Nanotechnol. *2*, 780–783. 10.1038/nnano.2007.388.
- Iyer, S., Gaikwad, R.M., Subba-Rao, V., Woodworth, C.D., and Sokolov, I. (2009). Atomic force microscopy detects differences in the surface brush of normal and cancerous cells. Nat. Nanotechnol. *4*, 389–393. 10.1038/nnano.2009.77.
- 61. Butcher, D.T., Alliston, T., and Weaver, V.M. (2009). A tense situation: forcing tumour progression. Nat. Rev. Cancer *9*, 108–122. 10.1038/nrc2544.

- Kennedy-Darling, J., Bhate, S.S., Hickey, J.W., Black, S., Barlow, G.L., Vazquez, G., Venkataraaman, V.G., Samusik, N., Goltsev, Y., Schürch, C.M., et al. (2021). Highly multiplexed tissue imaging using repeated oligonucleotide exchange reaction. Eur. J. Immunol. *51*, 1262–1277. 10.1002/eji.202048891.
- 63. Black, S., Phillips, D., Hickey, J.W., Kennedy-Darling, J., Venkataraaman, V.G., Samusik, N., Goltsev, Y., Schürch, C.M., and Nolan, G.P. (2021). CODEX multiplexed tissue imaging with DNA-conjugated antibodies. Nat. Protoc. *16*, 3802–3835. 10.1038/s41596-021-00556-8.
- 64. Hickey, J.W., Neumann, E.K., Radtke, A.J., Camarillo, J.M., Beuschel, R.T., Albanese, A., McDonough, E., Hatler, J., Wiblin, A.E., Fisher, J., et al. (2022). Spatial mapping of protein composition and tissue organization: a primer for multiplexed antibody-based imaging. Nat. Methods *19*, 284–295. 10.1038/s41592-021-01316-y.
- Hickey, J.W., Becker, W.R., Nevins, S.A., Horning, A., Perez, A.E., Chiu, R., Chen, D.C., Cotter, D., Esplin, E.D., Weimer, A.K., et al. (2021). 35672395. 2021.11.25.469203. 10.1101/2021.11.25.469203.
- Souza, R.F., and Spechler, S.J. (2022). Mechanisms and pathophysiology of Barrett oesophagus. Nat. Rev. Gastroenterol. Hepatol. *19*, 605–620. 10.1038/s41575-022-00622w.
- 67. Hickey, J.W., Tan, Y., Nolan, G.P., and Goltsev, Y. (2021). Strategies for Accurate Cell Type Identification in CODEX Multiplexed Imaging Data. Front. Immunol. *12*, 727626. 10.3389/fimmu.2021.727626.
- D'Alessio, F.R., Tsushima, K., Aggarwal, N.R., West, E.E., Willett, M.H., Britos, M.F., Pipeling, M.R., Brower, R.G., Tuder, R.M., McDyer, J.F., et al. (2009). CD4+CD25+Foxp3+ Tregs resolve experimental lung injury in mice and are present in humans with acute lung injury. J. Clin. Invest. *119*, 2898–2913. 10.1172/JCI36498.
- 69. DeFilippis, R.A., Chang, H., Dumont, N., Rabban, J.T., Chen, Y.-Y., Fontenay, G.V., Berman, H.K., Gauthier, M.L., Zhao, J., Hu, D., et al. (2012). CD36 repression activates a multicellular stromal program shared by high mammographic density and tumor tissues. Cancer Discov. *2*, 826–839. 10.1158/2159-8290.CD-12-0107.
- McDonald, S.A.C., Graham, T.A., Lavery, D.L., Wright, N.A., and Jansen, M. (2015). The Barrett's Gland in Phenotype Space. Cell. Mol. Gastroenterol. Hepatol. *1*, 41–54. 10.1016/j.jcmgh.2014.10.001.
- 71. Calon, A., Tauriello, D.V.F., and Batlle, E. (2014). TGF-beta in CAF-mediated tumor growth and metastasis. Semin. Cancer Biol. *25*, 15–22. 10.1016/j.semcancer.2013.12.008.
- 72. DeFilippis, R.A., Fordyce, C., Patten, K., Chang, H., Zhao, J., Fontenay, G.V., Kerlikowske, K., Parvin, B., and Tlsty, T.D. (2014). Stress signaling from human mammary epithelial cells contributes to phenotypes of mammographic density. Cancer Res. *74*, 5032–5044. 10.1158/0008-5472.CAN-13-3390.
- Hao, Y., Triadafilopoulos, G., Sahbaie, P., Young, H.S., Omary, M.B., and Lowe, A.W. (2006). Gene expression profiling reveals stromal genes expressed in common between Barrett's esophagus and adenocarcinoma. Gastroenterology *131*, 925–933. 10.1053/j.gastro.2006.04.026.

- 74. Tilman, G., Mattiussi, M., Brasseur, F., van Baren, N., and Decottignies, A. (2007). Human periostin gene expression in normal tissues, tumors and melanoma: evidences for periostin production by both stromal and melanoma cells. Mol. Cancer *6*, 80. 10.1186/1476-4598-6-80.
- 75. Park, J., and Scherer, P.E. (2012). Endotrophin a novel factor linking obesity with aggressive tumor growth. Oncotarget *3*, 1487–1488. 10.18632/oncotarget.796.
- 76. Williams, L., Layton, T., Yang, N., Feldmann, M., and Nanchahal, J. (2022). Collagen VI as a driver and disease biomarker in human fibrosis. FEBS J. *289*, 3603–3629. 10.1111/febs.16039.
- 77. Davidson, S., Efremova, M., Riedel, A., Mahata, B., Pramanik, J., Huuhtanen, J., Kar, G., Vento-Tormo, R., Hagai, T., Chen, X., et al. (2020). Single-Cell RNA Sequencing Reveals a Dynamic Stromal Niche That Supports Tumor Growth. Cell Rep. *31*, 107628. 10.1016/j.celrep.2020.107628.
- 78. Fuhrmann, A., Staunton, J.R., Nandakumar, V., Banyai, N., Davies, P.C.W., and Ros, R. (2011). AFM stiffness nanotomography of normal, metaplastic and dysplastic human esophageal cells. Phys. Biol. *8*, 015007. 10.1088/1478-3975/8/1/015007.
- 79. Northcott, J.M., Dean, I.S., Mouw, J.K., and Weaver, V.M. (2018). Feeling Stress: The Mechanics of Cancer Progression and Aggression. Front. Cell Dev. Biol. *6*, 17. 10.3389/fcell.2018.00017.
- 80. Li, J., Tan, J., Martino, M.M., and Lui, K.O. (2018). Regulatory T-Cells: Potential Regulator of Tissue Repair and Regeneration. Front. Immunol. *9*, 585. 10.3389/fimmu.2018.00585.
- Lagisetty, K.H., McEwen, D.P., Nancarrow, D.J., Schiebel, J.G., Ferrer-Torres, D., Ray, D., Frankel, T.L., Lin, J., Chang, A.C., Kresty, L.A., et al. (2021). Immune determinants of Barrett's progression to esophageal adenocarcinoma. JCI Insight *6*, e143888, 143888. 10.1172/jci.insight.143888.
- Gokon, Y., Fujishima, F., Taniyama, Y., Ishida, H., Yamagata, T., Sawai, T., Uzuki, M., Ichikawa, H., Itakura, Y., Takahashi, K., et al. (2020). Immune microenvironment in Barrett's esophagus adjacent to esophageal adenocarcinoma: possible influence of adjacent mucosa on cancer development and progression. Virchows Arch. Int. J. Pathol. 477, 825–834. 10.1007/s00428-020-02854-0.
- Wang, Z., Xiong, S., Mao, Y., Chen, M., Ma, X., Zhou, X., Ma, Z., Liu, F., Huang, Z., Luo, Q., et al. (2016). Periostin promotes immunosuppressive premetastatic niche formation to facilitate breast tumour metastasis. J. Pathol. 239, 484–495. 10.1002/path.4747.
- Gowhari Shabgah, A., Haleem Al-Qaim, Z., Markov, A., Valerievich Yumashev, A., Ezzatifar, F., Ahmadi, M., Mohammad Gheibihayat, S., and Gholizadeh Navashenaq, J. (2021). Chemokine CXCL14; a double-edged sword in cancer development. Int. Immunopharmacol. 97, 107681. 10.1016/j.intimp.2021.107681.
- Morra, L., and Moch, H. (2011). Periostin expression and epithelial-mesenchymal transition in cancer: a review and an update. Virchows Arch. Int. J. Pathol. *459*, 465–475. 10.1007/s00428-011-1151-5.

- 86. Martin, M. Cutadapt Removes Adapter Sequences From High-Throughput Sequencing Reads. EMBnet.journal *17*, 10–12. 10.14806/ej.17.1.200.
- 87. Bray, N.L., Pimentel, H., Melsted, P., and Pachter, L. (2016). Near-optimal probabilistic RNA-seq quantification. Nat. Biotechnol. *34*, 525–527. 10.1038/nbt.3519.
- Melsted, P., Booeshaghi, A.S., Liu, L., Gao, F., Lu, L., Min, K.H., da Veiga Beltrame, E., Hjörleifsson, K.E., Gehring, J., and Pachter, L. (2021). Modular, efficient and constantmemory single-cell RNA-seq preprocessing. Nat. Biotechnol. *39*, 813–818. 10.1038/s41587-021-00870-2.
- 89. Wolf, F.A., Angerer, P., and Theis, F.J. (2018). SCANPY: large-scale single-cell gene expression data analysis. Genome Biol. *19*, 15. 10.1186/s13059-017-1382-0.
- Wolock, S.L., Lopez, R., and Klein, A.M. (2019). Scrublet: Computational Identification of Cell Doublets in Single-Cell Transcriptomic Data. Cell Syst. 8, 281-291.e9. 10.1016/j.cels.2018.11.005.
- 91. Zheng, G.X.Y., Terry, J.M., Belgrader, P., Ryvkin, P., Bent, Z.W., Wilson, R., Ziraldo, S.B., Wheeler, T.D., McDermott, G.P., Zhu, J., et al. (2017). Massively parallel digital transcriptional profiling of single cells. Nat. Commun. *8*, 14049. 10.1038/ncomms14049.
- 92. McInnes, L., Healy, J., and Melville, J. (2018). UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction. ArXiv180203426 Cs Stat.
- 93. Wolf, F.A., Hamey, F.K., Plass, M., Solana, J., Dahlin, J.S., Göttgens, B., Rajewsky, N., Simon, L., and Theis, F.J. (2019). PAGA: graph abstraction reconciles clustering with trajectory inference through a topology preserving map of single cells. Genome Biol. *20*, 59. 10.1186/s13059-019-1663-x.
- 94. Traag, V.A., Waltman, L., and van Eck, N.J. (2019). From Louvain to Leiden: guaranteeing well-connected communities. Sci. Rep. *9*, 5233. 10.1038/s41598-019-41695-z.
- Speir, M.L., Bhaduri, A., Markov, N.S., Moreno, P., Nowakowski, T.J., Papatheodorou, I., Pollen, A.A., Raney, B.J., Seninge, L., Kent, W.J., et al. (2021). UCSC Cell Browser: visualize your single-cell data. Bioinformatics *37*, 4578–4580. 10.1093/bioinformatics/btab503.
- Osumi-Sutherland, D., Xu, C., Keays, M., Levine, A.P., Kharchenko, P.V., Regev, A., Lein, E., and Teichmann, S.A. (2021). Cell type ontologies of the Human Cell Atlas. Nat. Cell Biol. 23, 1129–1135. 10.1038/s41556-021-00787-7.
- Madissoon, E., Wilbrey-Clark, A., Miragaia, R.J., Saeb-Parsy, K., Mahbubani, K.T., Georgakopoulos, N., Harding, P., Polanski, K., Huang, N., Nowicki-Osuch, K., et al. (2019). scRNA-seq assessment of the human lung, spleen, and esophagus tissue stability after cold preservation. Genome Biol. *21*, 1. 10.1186/s13059-019-1906-x.
- Yang, S., Corbett, S.E., Koga, Y., Wang, Z., Johnson, W.E., Yajima, M., and Campbell, J.D. (2020). Decontamination of ambient RNA in single-cell RNA-seq with DecontX. Genome Biol. *21*, 57. 10.1186/s13059-020-1950-6.

- 99. Büttner, M., Ostner, J., Müller, C.L., Theis, F.J., and Schubert, B. (2021). scCODA is a Bayesian model for compositional single-cell data analysis. Nat. Commun. *12*, 6876. 10.1038/s41467-021-27150-6.
- 100. Sturm, G. (2022). infercnvpy: Scanpy plugin to infer copy number variation (CNV) from single-cell transcriptomics data.
- 101. Data-independent acquisition and quantification of extracellular matrix from human lung in chronic inflammation-associated carcinomas PubMed https://pubmed.ncbi.nlm.nih.gov/36228107/.
- 102. Escher, C., Reiter, L., MacLean, B., Ossola, R., Herzog, F., Chilton, J., MacCoss, M.J., and Rinner, O. (2012). Using iRT, a normalized retention time for more targeted measurement of peptides. Proteomics *12*, 1111–1121. 10.1002/pmic.201100463.
- 103. Gillet, L.C., Navarro, P., Tate, S., Röst, H., Selevsek, N., Reiter, L., Bonner, R., and Aebersold, R. (2012). Targeted data extraction of the MS/MS spectra generated by dataindependent acquisition: a new concept for consistent and accurate proteome analysis. Mol. Cell. Proteomics MCP *11*, 0111.016717. 10.1074/mcp.0111.016717.
- 104. Collins, B.C., Hunter, C.L., Liu, Y., Schilling, B., Rosenberger, G., Bader, S.L., Chan, D.W., Gibson, B.W., Gingras, A.-C., Held, J.M., et al. (2017). Multi-laboratory assessment of reproducibility, qualitative and quantitative performance of SWATH-mass spectrometry. Nat. Commun. *8*, 291. 10.1038/s41467-017-00249-5.
- 105. Schilling, B., Gibson, B.W., and Hunter, C.L. (2017). Generation of High-Quality SWATH® Acquisition Data for Label-free Quantitative Proteomics Studies Using TripleTOF® Mass Spectrometers. Methods Mol. Biol. Clifton NJ *1550*, 223–233. 10.1007/978-1-4939-6747-6_16.
- 106. Rosenberger, G., Koh, C.C., Guo, T., Röst, H.L., Kouvonen, P., Collins, B.C., Heusel, M., Liu, Y., Caron, E., Vichalkovski, A., et al. (2014). A repository of assays to quantify 10,000 human proteins by SWATH-MS. Sci. Data *1*, 140031. 10.1038/sdata.2014.31.
- 107. Storey, J.D. (2002). A direct approach to false discovery rates. J. R. Stat. Soc. Ser. B Stat. Methodol. *64*, 479–498.
- 108. Lee, M.Y., Bedia, J.S., Bhate, S.S., Barlow, G.L., Phillips, D., Fantl, W.J., Nolan, G.P., and Schürch, C.M. (2022). CellSeg: a robust, pre-trained nucleus segmentation and pixel quantification software for highly multiplexed fluorescence images. BMC Bioinformatics 23, 46. 10.1186/s12859-022-04570-9.
- 109. Bhate, S.S., Barlow, G.L., Schürch, C.M., and Nolan, G.P. (2022). Tissue schematics map the specialization of immune tissue motifs and their appropriation by tumors. Cell Syst. *13*, 109-130.e6. 10.1016/j.cels.2021.09.012.
- Schürch, C.M., Bhate, S.S., Barlow, G.L., Phillips, D.J., Noti, L., Zlobec, I., Chu, P., Black, S., Demeter, J., McIlwain, D.R., et al. (2020). Coordinated Cellular Neighborhoods Orchestrate Antitumoral Immunity at the Colorectal Cancer Invasive Front. Cell *182*, 1341-1359.e19. 10.1016/j.cell.2020.07.005.

Figure Legends

Graphical Abstract. To obtain a comprehensive picture of the coordinated changes in epithelial, stromal and immune compartments during development of Barrett's-associated esophageal adenocarcinoma, patient-matched samples corresponding to various phases of disease progression were collected from 12 patients, each of which had at a given time point lesions at multiple stages progression (matched-normal, metaplasia, dysplasia, and carcinoma). Matched "normal" gastric tissues were also collected. These sample were analyzed by single cell RNA-sequencing (scRNAseq) for single-cell resolution transcriptomics and Copy Number Variant (CNV), by proteomics for extracellular matrix (ECM) proteins, by Atomic Force Microscopy (AFM for tissue stiffness and by CODEX spatial proteomics imaging The integrative multi-omics analysis exposed drastic alterations in cell type composition and shifts in cell states in all three compartments. A large subpopulation of fibroblasts absent in the normal esophagus and characteristic of dysplasia and adenocarcinoma sample, that based on markers would indeed be considered cancer associated fibroblasts (CAF), appeared already in the metaplastic phase. This fibroblast subpopulation had transcriptomes virtually indistinguishable with fibroblasts of the cancer free gastric epithelium in these patients

Main Figures

Figure 1. Integrated multiomics analysis of the progression of Barrett's Esophagus (BE) to esophageal adenocarcinoma (EA). (A) Example of a surgical resection showing locations of samples representing the phases of disease progression and use in multiomic-analyses. (B) Gene markers (transcripts) used for classification of coarse-grained cell types from scRNAseq data. (C) UMAP visualization of the entirety of cells from all samples analyzed by scRNAseq color-labelled for clusters (Leiden unsupervised clustering), the coarse-grained cell types, tissue diagnosis, and patient IDs (clockwise from top left) obtained from scRNAseq. (D) UMAP visualization of all analyzed cells from all samples obtained from scRNAseq, color-labelled for the fine-grained cell type.

Figure 2. Overview of pseudo-bulk analysis. (A) Principal component analysis (PCA) displaying showing PC2 (x-axis) and PC3 (y-axis) of samples using pseudo-bulk transcriptome profiles for all cells (left panel), gastrointestinal (GI) epithelial cells (middle left panel), stromal cells (fibroblasts and endothelial cells) (middle right panel), and immune cells (T cells, B cells, Monocyte derived, Natural Killer (NK) cells, and dendritic cells (DC) (right panel)). Colors indicate the tissue diagnosis. (B) Heat maps showing changes in expression levels of selected genes (from left to right) for various pseudo-bulk schemes: all cells combined, gastro-intestinal (GI) epithelial cells, fibroblasts, endothelial cells and CD8 T cells at each phase of disease progression. (C) Heat map showing changes in expression levels of genes related to TGF-beta signaling in fibroblasts at each phase of disease progression.

Figure 3. Stromal and immune cell subtype composition changes during BE progression. (A) fibroblasts, (B) myofibroblasts, (C) endothelial cells, (D) T/Natural Killer (NK) cells, (E) myeloid cells (macrophages, monocytes, dendritic cells (DCs) and neutrophils), and (F) B/Plasma cells. **First column panels:** UMAP of cells from the respective cell type (including all diagnoses), color-coded by transcriptional cluster. **Second column panels:** Composition of cells with respect to cluster (subtype) membership, for each "diagnosis" (=phase of progression)/tissue with same color codes as in UMAPs. **Third column panels**: Selected marker genes for clusters of interest. **Fourth Column panels**: TOP subpanel: Statistically significant enrichment (red) or depletion (blue) of a cellular subtype at each diagnosis (compared to *mNE*, determined by scCODA, Methods). BOTTOM panel: Composition of cells with respect to the diagnoses, for each transcriptional cluster (subtype).

Figure 4. Large CNVs are markers of BE progression to malignancy. (A) For each epithelial cell of each sample (horizontal axis) representing the phases of progression (color labels), the CNV burden (vertical axis) was estimated based on inferred CNVs from scRNAseq (Methods). Most tumor samples contained cells with significantly increased CNV score compared to the *mNE/mNS* samples (black horizontal line: 99% quantile of CNV score in mNE/mNS cells). **(B)** Number of cells with (black) and without (grey) CNVs, according to cell type (left panel) and to disease progression phase (right panel). Large CNVs were restricted to the epithelial compartment and appeared at the dysplastic phase. **(C,D)** CNVs for tumor E21 inferred from scRNAseq (C) and were consistent with CNVs obtained from scDNAseq (D). **(E)** UMAP of epithelial cells in transcriptome space with each cell's CNV cluster membership identified in (C) shown in color (grey: CNVs absent). CNV clusters closely mimic transcriptional clusters.

Figure 5. Proteomic analysis and Atomic Force Microscopy (AFM) reveal changes in the extracellular matrix composition and tissue mechanics during BE progression. (A) Number of matrisome or matrisome-associated proteins detected by ECM proteomics grouped by protein class. (B) PCA of proteomic samples (mNE: green; T: red) shows differences in ECM-enriched protein extract composition between mNE and T samples. (C) Differential ECM protein abundances between mNE and T samples shows 43 and 55 proteins upregulated and downregulated in T compared to mNE, respectively. Proteins with the highest up/downregulation in T vs. mNE are identified. (D) Positive correlation between ECM proteomic- (y-axis) and respective scRNAseq (x-axis) fold-changes in matched samples. Proteins of interest are highlighted in red font. (E) Expression of significantly down-regulated (top panel) and upregulated (bottom panel) proteins identified by proteomic analysis (see C) grouped by scRNAseq cell type (including cells from all diagnoses). (F) Quantification of epithelium and stroma stiffness using AFM in a distinct cohort for the phases of progression, shown as violin plots. Each color represents an esophageal sample at a different phase from a given patient; included are here also samples from tumor-free individuals ("true normal") as opposed to the matched-normal" samples from EA patients. Donors: n=3, for matched normal esophagus, esophagus metaplasia, and dysplasia: n=4, for esophageal cancer and true normal esophagus: n=2 for matched normal stomach. Two-way Anova test with Tukey post hoc test was used as statistical test. Thick and thin dashed lines represent median and guartiles in the distribution, respectively. n = 50-150 regions per patient, ns: not significant, **** p < 0.001.

Figure 6. CODEX multiplexed proteomic imaging identifies epithelial and stromal tissue structures, exposing cell state changes. (A) Representative images of mNE, , M, D and T esophageal tissues from one patient (of a total of 5) from CODEX multiplexed fluorescent imaging for 6 of the 54 markers queried (scale bar = 500 um) and corresponding (B) coarse-grained, CODEX-defined epithelial cell types mapped back to tissue coordinates. (C) Neighborhood (NH) maps for mNE and M. (D) Percentage of metaplasia, as determined by a pathologist (*y*-axis) versus percentage of the "Specialized" NH from CODEX analysis of each of the 27 regions imaged (*x*- axis). (E) Magnified region of NH map for M sample shown in C (scale bar = 100 um). (F) Community (neighborhood of neighborhoods) maps for representative mNE (left panel) and M (right panel) samples. (G) Percentage of squamous (mNE) esophagus,

metaplasia (*M*), high grade dysplasia (HGD), and invasive EAC epithelium as determined by a pathologist (*y*- axis) versus percentage of community determined by CODEX for each of the 27 regions imaged (*x*-axis). (H-J) Cell type composition for each of the 4 communities (*mNE*: grey; *M*: purple; *D*: green; *T*: pink) that correlated with diseased epithelial in panel G, broken down by (H) epithelial, (I) immune, and (J) mesenchymal groupings. Percentages are provided in Suppl.Table S10. (K) cell-cell interaction analysis with -log(p-value) for each cell type pair compared to 10,000 random permutations, colored by overall disease state. (L-N) Representative images of the phases or progression: *mNE* (panel L), *D* (M), and *T* (N) from one donor (5 donors total) from CODEX imaging for 6 of the 54 markers queried (scale bar = 500 um) and of magnified regions (scale bar = 50 um). (O) Shannon's Diversity for cell types and proportions within each CODEX-defined community. (P) Schematic representation of overall changes in epithelial and stromal connections.

Supplemental Figures

Figure S1. Description of clinical samples and multi-omics analyses conducted. (A) Table describing the samples analyzed in this study including sampling method (surgical resection (SR) or endoscopic biopsy (B)), tissue diagnosis (*mNE*: matched Normal Esophagus, *M*: Barrett's metaplasia, *D*: dysplasia, *T*: tumor, *mNS*: matched Normal Stomach - other abbreviations indicate a mixture of tissue types), type of analysis performed and specimen ID. **(B)** Selection of pathohistological images of scanned hematoxylin and eosin-stained tissue sections independently assessed by two expert esophageal pathologists to confirm tissue diagnosis.

Figure S2. Overview of sample space and global cell type survey. (A) UMAP visualization for non-batch corrected scRNAseq data of all analyzed cells across all histological diagnoses (progression phases), color-coded by cluster. Note that the non-batch corrected data show separation into patient-specific cancer cells. (B) UMAP visualization for batch corrected scRNAseq data of all analyzed cells across all histological diagnoses, color-coded by cluster. (C) Cells color-coded for predicted cell cycle phase (Methods). Subsets of epithelial tumor cells and T cells appear highly proliferative (G2M phase, green). (D) Fraction of proliferating cells (S or G2M phase) color-coded for each patient for each cell type and phase of progression (diagnosis). Error bars denote 5% and 95% Bayesian credibility intervals of a binomial model.

Figure S3. Cell type-specific signatures of gene expression changes during BE progression. Differential gene expression at each phase of progression (diagnosis) based on pseudo-bulk transcriptomes, for 8 major cell types. The observed gene expression patterns specific for various cellular compartments illustrate profound epithelial, stromal and immune tissue alterations associated with disease progression.

Figure S4. Cell type composition changes during BE progression. (A) TOP: Clustering of individual samples based on cell type composition (proportions) Each sample's diagnosis is indicated above the dendrogram. BOTTOM: Epithelial, stromal and immune percentages of each sample (aggregated from cell type proportions used for clustering) are shown in the heatmap below the dendrogram. (B) Sample level PCA performed with pseudo-bulk gene expression measures showed that the variation in the PCA was largely due to variation in cell type quantities as shown by correlation with the principal coordinates and cell type proportions across samples. (C) Cell type proportions (as shown in A) collapsed by diagnosis. (D) Significant changes in cell type composition across diagnoses. Statistically significant changes with respect to *mNE* (determined by scCODA, see Methods) are shown above the bar graph

(red: upregulated, blue: down-regulated). **(E)** Normalized expression of differentiation markers in epithelial cells across the different phases of disease progression shows a loss of differentiation at the D/T phase of progression.

Figure S5: Copy number profile (A) and distribution of copy number clusters/clones across samples and diagnoses (B) inferred from scRNAseq. While dysplastic (*D*) cells (samples E07C and E07D1) form their own CNV clusters (clones 18 and 37), cells from matched T (sample E07B) show similar CNVs (clone 21), e.g., a gain of chr6p and a loss of chr6q indicating a clonal relationship between *D* and *T*.

Figure S6. Protein abundance changes in EAC (7) compared to matched normal esophagus (mNE). (A) Top 10 proteins with most altered abundance detected in ECMenriched samples or T vs. mNE tissues. (B) Core matrisomal protein signatures altered in T versus mNE.

Figure S7. (A) Identification of likely cell source of proteins with altered abundances during BE progression. Gene expression fold changes in scRNAseq pseudo-bulk analysis were queried for proteins that were identified as differentially abundant in the ECM proteomic analysis, i.e., either decreased (left panel) or increased (right panel) in *T* vs. *mNE*, respectively (Fig. 5 and Table S5). Cell type specificity and abundance for each transcript is displayed as circles (color-coded for cell type and size-scaled for cell abundance). **(B)** Plots with changes in mRNA expression of periostin (POSTN) inferred from scRNAseq data, grouped by cell type and diagnosis, reveals complexity changes that depends on cell source (shown in A).

Figure S8. AFM mechanics is consistent with a shift in tissue identity from *squamous* esophagus to *BE* (esophagus to stomach).

(A) Workflow of sample preparation for AFM stiffness measurements. (B) Stromal and epithelial esophagus stiffness gradients were compared at various phases of progression to EAC. Representative H&E images and corresponding AFM stiffness maps showing difference between stroma and epithelium stiffness at different phases of esophageal cancer progression and comparison with matched normal squamous esophagus (i.e., *mNE* adjacent to *BE* and tumor) and true normal (disease-free) squamous esophagus tissues. Dashed lines indicate the interface between stroma (S) and epithelium (E). Scales: 200 μ m.

Figure S9. Cell type-specific analysis from CODEX multiplexed proteomics imaging of samples corresponding to disease progression phases of BE-associated EAC.

(A) Schematic for overall approach to image tissues with CODEX imaging. (B) Representative H&E image taken after CODEX imaging with percentage of diagnosis (based on epithelial cell histology) labeled by pathologists. (C-D) Quantification of epithelial percentage (*y*-axis) for each overall (C) sub and (D) major diagnosis by pathologist from the H&E stain of the tissue section following CODEX multiplexed imaging. (E) Average protein expression (*x*-axis) by cell type (*y*-axis) derived from the clustered CODEX multiplexed imaging data. (F) Epithelial cell type percentages across the different disease phases as diagnosed by pathologists.

Figure S10. Comparison of cell type abundances across patients analyzed by both scRNAseq (A, C) (clinical samples) and CODEX (B, D) (adjacent tissue regions) grouped by sample (A, B) and diagnosis (C, D).

Figure S11. Multicellular Neighborhood (NH) analysis by CODEX imaging reveals multicellular neighborhood tissue reorganization during the progression of BE to EAC. (A) Maps of multicellular neighborhoods mapped back to original coordinates for one

representative patient (5 patients total). **(B)** Definition of NHs based on cell types enrichment (red) or depletion (blue) within individual neighborhoods identified in Figure S8E. Rows represent hence -identified NHs, and their name given on the left. **(C)** Percentage of "Apical Squamous" NH within the different progression phases. **(D)** Average percentage of the epithelial neighborhoods within each of the phases as determined by a pathologist post H&E staining. **(E)** Percentage of high-grade (HG) dysplastic epithelium as determined by a pathologist (*y*-axis) versus percentage of "Stroma and Neutrophil" NH determined by CODEX for each of the 27 regions imaged. **(F)** Percentage of "Specialized" NH within the different disease phases. **(G)** Percentage of epithelial cell types within the "Specialized" NH.

Figure S12. Community (Neighborhood of neighborhoods) analysis of CODEX imaging illustrates the dynamic rearrangements of intricate epithelial-stromal cell entities during **BE progression.** (A) Percentage of epithelial cells as determined by a pathologist (y axis) versus percentage of the neighborhoods as determined by CODEX for each of the 27 regions imaged with correlations. (B) Neighborhoods enriched or depleted within individual communities identified. (C) Maps of communities mapped back to original coordinates for one representative example donor. Community color code is the same as in B. (D-E) Percentage of cell type within each community that correlated with pathologist-classified epithelium for (D) epithelial cell types and (E) neutrophils. (F) Percentage of neighborhoods within each community that correlated with pathologist-classified epithelium. (G-H) Percentage of cell type within each community that correlated with pathologist-classified epithelium for (G) macrophage phenotypes and (H) CD4+ Tregs. (I) Percentage of CD4+ Tregs in progression phases. (J) Percentage of CD4+ Tregs versus percentage of CD36hi endothelial cells within the same sample imaged.

Figure S13. Cell-cell interaction analysis from CODEX images reveals dynamic and increasingly diverse cell interaction pairs during BE progression. (A-C) Significant (average *p*-value <0.05) cell-cell interactions shown for (A) metaplasia, (B) dysplasia, and (C) tumor classified samples. (D) Cell-cell pairs found enriched in *M*, *D* and *T* disease phases with dashed line representing a p value of 0.05. (E-F) Percentage of (E) plasma cells and (F) CD36hi endothelial cells found across different disease phases. (G-I) Subset of cells identified by CODEX imaging replotted to tissue coordinates for (G) metaplasia, (H) dysplasia, and (I) tumor samples.

Supplemental Tables

Table S1. Patient and biosample metadata. Patient information, biosample descriptions, and histological diagnosis are provided for 64 samples.

Table S2. Coarse grained differentially expressed genes. For each of 16 coarse grained cell types, differential expression was calculated comparing phases of progressing with DESeq2 and the pseudo-bulk transcriptomes per biosample. Results were filtered through association testing with the ambient RNA from empty droplets.

Table S3. Fine grained gene markers. Gene markers of fine grained cell types based on statistical differential expression analysis between clusters.

Table S4. Fibroblast pathway signature scores. Using the DEGs of fibroblasts, B cells, natural killer cells (NK) and monocyte-derived cells, selected pathways were tested for association using Enrichr. Inputs were DEGs filtered to have at least a log2 fold change of 0.58 and adjusted p-value of 0.05.

Table S5. Patient cell counts. From the single cell RNA-seq data, counts of both coarse grain and fine grained cell types per patient.

Table S6. ECM Proteomic differential abundance statistics. Comparing ECM protein abundance between pooled Tumor (T) samples versus matched Normal Esophagus (mNE) samples using paired T-tests with multiple testing correction.


Table S7. ECM Proteomics DIA isolation scheme. Samples were analyzed for ECM protein abundance by data-independent acquisition (DIA) using variable-sized windows covering the m/z 400-1,250 range.


Table S8. CODEX Pathology concordance. Using imaging data from 5 human donors, three pathologists independently evaluated the H&E staining of the sections performed on the same tissue sections that were used for the CODEX multiplexed imaging. Pathologist scores were then aggregated and averaged for disease phase granular diagnosis (e.g., mNE, mNS, M), and estimated percentages of type of epithelium in each image (e.g., % squamous, % metaplasia, % dysplasia, % tumor).

Table S9. CODEX antibody information. The antibody panels used in generating CODEX data were chosen to include targets that identify subtypes of intestinal epithelium and stromal cells, and cells of the innate and adaptive immune system.


Table S10. CODEX communities. Percentages of cell type composition for each of the 4 communities (mNE: grey; M: purple; D: green; T: pink) that correlated with diseased epithelial, broken down by epithelial, immune, and mesenchymal groupings.

Table S11. CODEX neighborhood analysis. Spatial neighborhood (NH) information was used for cell-cell interaction statistics across progression phases (M, D, T). The frequency of neighbors, using a nearest neighbor approach, was compared to the frequency of occurrences in null-models, achieved by 10,000 permutations of cell type locations.






В




GI epithelial cells



Average gene expression across tissues

Endothelial cells AMP3 CPPED1 CRISPLD1 ե CUBN USB1 ſſ UBTD1 BMP1 MBOAT7 CLCN5 DUSP8 LGALS9 HLF нохаз ſ FAXDC2 FBXO21 EIF4E3 F FMO5 HECTD2 ł AHNAK2 ZCCHC7 FAM13C ſ RASA1 ST6GALNAC1 mNEM D T mNS



Norm. avg. expression

1.5

1.0

0.5

0.0


-0.5

-1


С

Fibroblast expression of genes related to "TGFb regulation of ECM"

mNEM D T mNS



Norm. avg. expression 1.5 1.0 0.5 0.0 -0.5 -1



Mean expression in cluster

Log2 FC of proportion (wrt mNE)

Venous

VSMC

Α

В

С

D

NK

Ε


3


Macrophage


Pan-tissue


.


F

















Diagnosis











Sample dendrogram based on











A. bTopp10 proteins most /altered in abundance detected in EGM preparation of tumor vs. normal esophagus


UniProt IDs	Genes	Protein Names	Protein Descriptions	Log2 (FC)	Log2 (FC)	Ratio	Qvalue
Q09666	AHNAK	AHNK_HUMAN	Neuroblast differentiation-associated protein AHNAK	-3.93	3.93	0.07	1.85E-75
P15924	DSP	DESP_HUMAN	Desmoplakin	-3.02	3.02	0.12	1.06E-51
P12111	COL6A3	CO6A3_HUMAN	Collagen alpha-3(VI) chain	-2.13	2.13	0.23	4.03E-47
P48668	KRT6C	K2C6C_HUMAN	Keratin, type II cytoskeletal 6C	-6.25	6.25	0.01	2.94E-42
P13647	KRT5	K2C5_HUMAN	Keratin, type II cytoskeletal 5	-7.68	7.68	0.00	2.78E-32
P17661	DES	DESM_HUMAN	Desmin	-5.23	5.23	0.03	4.23E-28
P19013	KRT4	K2C4_HUMAN	Keratin, type II cytoskeletal 4	-6.58	6.58	0.01	4.32E-27
Q14315	FLNC	FLNC_HUMAN	Filamin-C	-2.86	2.86	0.14	1.16E-26
P02675	FGB	FIBB_HUMAN	Fibrinogen beta chain	4.58	4.58	23.91	5.89E-26
P13646	KRT13	K1C13_HUMAN	Keratin, type I cytoskeletal 13	-8.08	8.08	0.00	6.28E-25

q-value < 0.001 & absolute Log₂(FC) > 0.58

B. Matrisomal proteins altered in Tumor versus normal (patient-matched) esophagus

Genes	UniProt ID	Protein Descriptions	Matrisome Categories	Tumor vs Matched Normal				
ANXA1	P04083	Annexin A1	ECM-affiliated proteins	-2.86				
ANXA4	P09525	Annexin A4	ECM-affiliated proteins	1.88				
COL14A1	Q05707	Collagen alpha-1(XIV) chain	Collagens	-2.39				
COL6A1	P12109	Collagen alpha-1(VI) chain	Collagens	-1.78				
COL6A2	P12110	Collagen alpha-2(VI) chain	Collagens	-1.81				
COL6A3	P12111	Collagen alpha-3(VI) chain	Collagens	-2.13				
COL7A1	Q02388	Collagen alpha-1(VII) chain	Collagens	-4.00				
FBN1	P35555	Fibrillin-1	ECM glycoproteins	1.41				
FGA	P02671	Fibrinogen alpha chain	ECM glycoproteins	5.69				
FGB	P02675	Fibrinogen beta chain	ECM glycoproteins	4.58				
FGG	P02679	Fibrinogen gamma chain	ECM glycoproteins	5.71				
LAMA4	Q16363	Laminin subunit alpha-4	ECM glycoproteins	-1.32				
LAMA5	015230	Laminin subunit alpha-5	ECM glycoproteins	-0.98				
LAMB2	P55268	Laminin subunit beta-2	ECM glycoproteins	-1.75				
LAMC1	P11047	Laminin subunit gamma-1	ECM glycoproteins	-1.08				
NID1	P14543	Nidogen-1	ECM glycoproteins	-2.10				
POSTN	Q15063	Periostin	ECM glycoproteins	0.78				
PRELP	P51888	Prolargin	Proteoglycans	-2.70				
PRG2	P13727	Bone marrow proteoglycan	Proteoglycans	5.31				
PRG3	Q9Y2Y8	Proteoglycan 3	Proteoglycans	3.43				
\$100A16	Q96FQ6	Protein S100-A16	Secreted factors	-3.55				
VWA1	Q6PCB0	von Willebrand factor A	ECM glycoproteins	-1.71				
Log ₂ (FC)								
		Lowest 0	Highest					
display	Log ₂ (FC) for the significan	tly altered protein	IS				


Upregulated (mNE->T) genes in ECM proteomics




Α

В







¹⁰⁰ S

200 40 μm

0

Е


40 µm


-12 S


40 µm


Е

0










Proportion





 \diamond \checkmark

1st

